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Abstract 
Background: PIK3CA is the only frequently mutated, druggable oncogene in head and neck 
squamous cell cancer (HNSCC), with PIK3CA point mutations and gene amplification rates 
of 17.5% and 40% respectively, with higher rates in HPV-positive disease. The objective of 
this research was to determine the effects of BYL719, an α-specific PI3K inhibitor in 
HNSCC cell lines.  
Hypothesis: All cell lines with PIK3CA hotspot point mutations or gene amplifications will 
be sensitive to BYL719.  
Methods: Twenty-eight HNSCC cell lines were subjected to increasing concentrations of 
BYL719 and cell viability was measured over time. Cell lines were screened for activating 
PIK3CA hotspot mutations and amplifications by real time PCR. Activity of PI3K pathway 
members was determined by immuniblot. 
Results: All PIK3CA cell lines with hotspot point mutations were sensitive to BYL719 
treatment, whereas all PIK3CA amplified cell lines were resistant. Moreover, resistant cell 
lines showed persistent protein activation of mTORC1, as determined by continued 
phosphorylation of ribosomal protein S6 following BYL719 treatment. Combination drug 
therapy with rapamycin, an mTORC1 inhibitor, reduced cell viability in BYL719-resistant 
cell lines. Nearly all PIK3CA amplified cell lines showed co-amplification of PIK3CA with 
SOX2 genes. Theses findings will help determine which population of patients will benefit 
most from BYL719 treatment. 
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1 INTRODUCTION – Genomic predictors of drug response to 
the alpha-specific phosphoinositol 3-kinase (PI3Kα) inhibitor 
BYL719 in head and neck cancers 
1.1 Introduction to Head and Neck Cancer 
 Head and neck squamous cell cancer (HNSCC) includes malignant squamous cell 
lesions arising in the oral cavity, nasal cavity, larynx, and pharynx. It is the sixth most 
common cancer by incidence worldwide, with approximately 600,000 new diagnoses per 
year (1). Despite significant advances in our understanding of the disease, the mortality 
rate has remained relatively high, with an estimated annual death toll of 355,000 (2).  
 Head and neck cancers have long been known to be caused by heavy tobacco 
and/or alcohol use (2,3,4). Government initiatives aimed at curbing smoking use were 
established in the 1960s and have been largely successful (4). Paralleling this decline in 
smoking was a decrease in smoking-related head and neck cancers (4), and as such, the 
number of patients presenting with tobacco or alcohol-induced HNSCC declined (5). 
These patients were older individuals with poorer overall health, and tumors most 
commonly found in the oral cavity and larynx (5). More recently, however, there has 
been a dramatic rise in the number of oropharyngeal cancers, now recognized to be 
caused by oral infection with human papillomavirus (HPV). This increase in incidence of 
HPV-related HNSCC has been described by some as a slow epidemic (3). 
 Tumors of the head and neck possess a large degree of heterogeneity with few 
consistent mutations across patient cohorts, underscoring the difficulty in identifying 
effective molecular targeting agents that will benefit a substantial population of HNSCC 
patients (6-11). The majority of HNSCC tumors have loss of function (LOF) mutations in 
tumor suppressor genes, thereby making effective drug targeting challenging (6,8,9-11). 
This is because it is much more difficult to reintroduce a gene product that has been lost, 
rather than target a gene product that is overactive (6,7). Compounding the problem is the 
rising incidence of HPV-driven HNSCCs, as HPV-induced and traditional HPV-negative 
HNSCCs are very distinct diseases with divergent clinical manifestations and treatment 
outcomes (6,12). 
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 Tobacco and alcohol act as mutagenic agents by damaging cellular DNA, and 
introducing mutations in vital DNA repair genes. In contrast, HPV-related tumors express 
viral oncoproteins (e.g. E6 and E7), which function to inhibit and degrade critical tumor 
suppressor genes (e.g. p53 and the retinoblastoma protein (pRb) respectively), thereby 
overriding these critical cellular control mechanisms without the introduction of cellular 
gene mutations (12). Consistent with this mechanism, HPV-negative HNSCCs have been 
found to harbor more than twice as many mutations as HPV-positive HNSCC tumors 
(4.83 mutations/Mbp and 2.28 mutations/Mbp, respectively) (6). Many of the mutations 
in both types of HNSCC tend to occur in key tumor suppressor genes, particularly TP53, 
which is almost ubiquitously mutated in all HPV-negative HNSCCs (6,8,9-11, TCGA 
www.cbioportal.org). High incidences of CDK2NA loss (p16INK4A, p14ARF) and/or 
CCND1 gain (Cyclin D1) are also very common, and provide a means for aberrant cell 
cycle control (6,9,10).  
 HPV-positive patients fare better than HPV-negative patients as shown by 
increased progression-free survival and overall survival when treated with platin-based 
concurrent chemoradiation (13, 14). HPV-positive HNSCC patients also had significantly 
lower rates of distant metastases as well as lower incidences of secondary primary tumors 
(13). Moreover, tobacco smoking on its own, independent of the causative nature of a 
patient’s HNSCC, has a significant impact on both variables in that the risks of death or 
cancer relapse increase by 1% for each additional pack-year of tobacco smoking (13). 
The lack of LOF mutations in key cell cyle regulators, particularly TP53, in HPV-
positive patients (6-11) may explain why HPV-positive HNSCC patients fare better than 
HPV-negative HNSCC. Poeta and colleagues published a large multicenter study 
analyzing TP53 status in 420 HNSCC patients and found patients with TP53 mutations 
showed a 1.5-fold decrease is survival compared to patients with wild-type TP53 (15). 
Tumors with LOF TP53 mutations also tend to respond significantly more poorly to 
cisplatin and 5’fluorouracil-based chemoradiation (16), and are associated with local 
recurrence after radiotherapy (17) as compared to TP53-WT tumors.  
 Generally, HPV-negative tumors have a higher frequency of transversions at CpG 
sites, which is characteristic of smoking malignancies (6). In contrast HPV-positive 
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tumors have more transitions at TpC sites based on TCGA data, and despite having fewer 
overall mutations, tend to have higher mutations in the PIK3CA (p110α) oncogene 
compared to HPV-negative tumors (6-10).  
Our knowledge of head and neck cancer etiology and progression has 
significantly increased over the past thirty years, yet mortality rates have remained 
consistent (2,12). Despite a favorable prognosis for most HPV-positive patients, 
approximately 20% fail therapy, with more than half due to distant metastases (18). In 
contrast, HPV-negative patients are at a higher risk of local, regional and distant relapse, 
with approximately 50% succumbing to the disease (1).  
In addition to mortality, both the disease as well as its treatment can often have 
marked patient morbidity. Indeed, HNSCC is unique as treatments often impact the most 
personal characteristics of what defines an individual, including facial appearance, and 
the ability to eat and speak. Other frequent side effects include pain, fibrosis, hearing 
loss, renal impairment and neurotoxicity (19). Thus, there are tremendous clinical 
challenges to deliver effective therapy that maximizes cure, while minimizing these 
sequelae.  
1.2 Next-Generation Sequencing of HNSCC  
 The advent of next-generation sequencing (NGS) has revolutionized the field of 
genomics. It is now possible to routinely extract an organism’s nucleic acids, and perform 
large-scale, cost effective and highly accurate genome-scale sequence data acquisition. In 
cancer research, the clearest advances have been obtained by sequencing tumors along 
with matched normal DNA from patient blood. This strategy allows exclusion of 
germline variants to report solely somatic changes. To date, there have been no reported 
germline mutations that predict HNSCC suceptability (6,9,11). Moreover, it has furthered 
our appreciation of the small number of true “driver” mutation events masked in a large 
population of “passenger” mutations (20). Bioinformatic analysis of patient tumors will 
allow medical professionals to identify gene mutations in key signaling pathways. It then 
becomes important to determine which mutations are responsible for carcinogenesis (20). 
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 A mutation is defined as a change in the nucleotide sequence of the genome (20). 
Point mutations are the replacement of one nucleotide for another, or the insertion or 
deletion of nucleotides (20). These changes can either be synonymous, where no change 
in the amino acid sequence is observed, or nonsynonymous, where the amino acid 
sequence is altered (20). With nonsynonymous mutations, the resulting protein can either 
be misfolded, truncated, or maintain proper function in the case of conserved amino acid 
changes (20). Moreover, by the definition above, gene amplifications or deletions, as well 
as chromosomal translocations are also considered mutations. Gene amplifications are 
copy number gains above the normal diploid number, and deletions are losses of one 
gene copy (heterozygous) or both copies (homozygous). Chromosomal translocations are 
the rearrangement of parts between nonhomologous chromosomes (20). 
The first NGS screens of HNSCC patient tumors described mutational events in 
key cell cycle components, as well as downstream effectors of mitogenic signaling 
(6,11). Additional discoveries included mutations in cell differentiation pathways, 
particularly NOTCH1 and FXBW7 (11). Recent studies have also identified incidences of 
mutations in pathways that influence terminal differentiation, cell proliferation, as well as 
apoptosis (6-11). A full, detailed summary of HNSCC NGS studies can be found in a 
review recently published by our group (Rizzo et al., Oral Disease 2014). Many of the 
mutations found in HNSCC are in tumor suppressors (6,9-11, TCGA 
www.cbioportal.org), which makes effective drug targeting challenging as there are no 
current effective stategies to target these agents (6,7). However two oncogenes, PIK3CA 
and HRAS, were found to be altered in a major subset of both HPV-positive and HPV-
negative HNSCC tumors, of which only PIK3CA is amenable to drug targeting (6-10).   
 Indeed several groups have confirmed high incidences in HNSCC of mutations in 
not only PIK3CA but also in other members of the PI3K/AKT pathway, albeit the rate of 
PIK3CA mutation/amplification is markedly higher (7,9,10). This is suggestive of a high 
dependency on this pathway for oncogenesis (22-25). One study showed that PIK3CA 
mutation/amplification, as well as PTEN inactivation by gene copy loss or mutation 
occurred at high frequencies in both aggressive HPV-positive and HPV-negative tumors 
(9,10). This has been confirmed in an additional study that demonstrated multiple 
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mutations in the PI3K signaling axes are only found in advanced stage (Stage IV or 
higher) HNSCC (7). Considering the high rate of PI3K/AKT pathway alterations in 
locoregional disease, coupled with reports of additional mutations (e.g. PTEN loss, HRAS 
mutations) as the disease progresses, implies that the PI3K/AKT pathway plays an 
important role across the whole timeline of cancer development.   
1.3 PI3K/AKT Pathway 
 The phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/AKT (protein kinase 
B) signaling cascade is the most commonly mutated pathway in cancers (6-11,22-25). 
Class I PI3Ks phosphorylate phosphatidylinositol to its more highly phosphorylated 
derivatives, generating second messengers that control proliferation, survival, motility 
and morphology (26). Class I PI3Ks are further subdivided into two classes, IA and IB 
(27). The class IA PI3Ks consist of PI3Kα, PI3Kβ, which are expressed in most tissues, 
and PI3Kδ, which is expressed in leukocytes (27). The class IB PI3K is the PI3Kγ, which 
is also found in leukocytes (27). Structurally, they are composed of a regulatory subunit 
(p85), which contains a src-homology (SH2) domain, and a catalytic subunit (p110), 
which has a RAS-binding domain (28). This complex is pre-formed but inactive in the 
cytoplasm of resting cells, waiting for appropriate cues for activation (28). The binding of 
the p85 SH2 domain to particular phosphotyrosine residues, often in response to receptor 
tyrosine kinase (RTK) activation, localizes the PI3K complex to the plasma membrane 
where it phosphorylates phosphatidylinositol-4,5-bisphosphate (PIP2) to its active 
phosphatidylinositol-3,4,5-triphosphate (PIP3) form (Figure 1). Activation of PI3K-alpha 
(PI3Kα) is postulated to occur by one of two mechanisms: first, the localization of the 
PI3K complex to the plasma membrane places p110α in close proximity with its lipid 
substrates (28), or the RTK-p85 subunit binding interaction changes the conformation of 
the complex allowing activation of kinase activity (28-30). PIP3 localizes and activates 
phosphoinositide-dependent protein kinase (PDK1) which then phosphorylates AKT at 
threonine 308 (29,31). Eventually, mammalian target of rapamycin (mTOR) inhibition is 
alleviated by AKT phosphorylation of the tuberous sclerosis complex (TSC1/2) proteins. 
TSC1/2 is a GTPase-activating protein, which catalyzes the conversion of GTP to GDP in 
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RHEB thereby suppressing mTOR activity (31). TSC1/2 complex phosphorylation 
inactivates the complex, allowing RHEB to bind GTP and activate mTOR (32).  
 mTOR kinases can be found in two distinct complexes, mTORC1 and mTORC2. 
mTORC1 is a multi-subunit complex composed of mTOR, the regulatory-associated 
protein of TOR (Raptor), the Gβ-like protein GβL, the proline-rich AKT substrate 40 kDa 
(PRAS40), and the DEP-domain-containing mTOR-interacting protein (Deptor). 
mTORC2 is composed of mTOR, rapamycin-insensitive companion of TOR (Rictor), 
GβL, mammalian stress-activated protein kinase interacting protein (mSIN1), protein 
observed with Rictor-1 (Protor-1), and Deptor (29,31). Individually, these complexes 
have distinct targets, with mTORC1’s role in the cell being particularly widespread, with 
important roles in cell growth and metabolism (24,31,33,34). Only mTORC1 is sensitive 
to rapamycin (sirolimus) treatment (33). This is because inhibition of mTORC2 lacks the 
FK506-binding protein of 12 kDa (FKBP12)-Rapamycin Binding (FRB) domain of 
mTOR, and therefore is unresponsive to FKBP12-rapamycin binding and inhibition (33).  
 In terms of relevancy for this thesis, mTORC1 plays an important role in protein 
synthesis (33). mTORC1 activation leads to the phosphorylation of the eukaryotic 
initiation factor 4E (eIF4E)-binding protein (4E-BP) and the p70 ribosomal S6 kinase 1 
(S6K1), inhibiting the former and activating the latter (31,33). 4E-BP inhibition promotes 
cap-dependent translation by allowing the formation of the eIF4F complex (31,33,35). 
Activation of S6K1 activates in turn the S6 ribosomal subunit thereby allowing proper 
ribosomal assembly and the translation complex to form (33). Both 4E-BP and S6 
phosphorylation are surrogate markers of mTORC1 activity (31,33,39). mTORC1 has 
also been shown to play important roles in regulating autophagy (36), lipid sysnthesis 
(37), and mitochondrial function (38). 
  
 Figure 1 PI3K AKT pathway signal transduction in protein synthesis. 
activation and interaction with the SH2 domain of the PI3K regulatory subunit p85 leads 
to the activation of the catalytic p110
PIP2 to PIP3. As a result, both PDK1 and AKT are recruited to the plasma membrane 
where AKT is phosphorylated at Threonine 308 by PDK1. Full activation of AKT is 
postulated to occur by the phosphorylation of a secondary site at Serine 473 by 
mTORC2. AKT phosphor
function and allowing RHEB to bind GTP and activate mTORC1. mTORC1 then 
phosphorylates the 4E-BP and the S6K, inhibiting the former and activating the latter, 
allowing the eIF4F complex to form, conc
eIF4F complex allows 5’ cap
proper ribosomal and translational machinery assembly. 
 
α subunit and the subsequent phosphorylation of 
ylates the TSC1/2 complex, thereby inhibiting its GTPase 
urrently with S6 phosphorylation. As such, the 
-dependent translation and the S6 phosphorylation permits 
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 The role of mTORC2 in the cell is much less well characterized than mTORC1, 
yet it is known to potentially facilitate the full activation of AKT by phosphorylating a 
secondary site at serine 473 (Figure 1) (33,39), however DNA-dependent protein kinase 
(DNA-PK) and ataxia telangiectasia mutated kinase (ATM) are also postulated to play a 
similar role (40). Loss of mTORC2 however does not affect TSC1/2 phosphorylation 
(33). The primary role of mTORC2 is thought to be in actin cytoskeleton remodeling 
(31).  
 In normal physiology, PI3Ks are negatively regulated by the tumor suppressor 
phosphatase and tensin homolog (PTEN), which catalyzes the reverse reaction from 
active PIP3 to inactive PIP2 (41). In some cancers, loss of PTEN either through focal 
deletion or loss of function mutation causes aberrant activation of the PI3K/AKT 
signaling axis, evident by high levels of AKT phosphorylation (31-34,39,41).   
1.3.1 PI3K/AKT Pathway in Cancer 
 Aberrant PI3K/AKT signaling is activated through somatic mutations, RTK 
stimulation, particularly the epidermal growth factor receptor (EGFR) and the insulin-like 
growth factor receptor 1 (IGF-1R), PTEN loss, or G-protein coupled receptors (GPCR) 
(33,43,44). This pathway has even been suggested to be so important to oncogenicity that 
cancer cells will actively maintain a certain homeostatic level of PI3K/AKT signaling in 
face of therapeutic intervention (45). Tuberous sclerosis (TSC) is an autosomal dominant 
disorder characterized by the formation of hamartomas due to LOF mutations in either 
TSC1 or TSC2, the key negative regulators of mTORC1 activity (46). Moreover, 
germline mutations in PTEN result in Cowden’s disease, a multi-organ disease 
characterized by benign hamartomatous growths (47,48). Both of these syndromes lead to 
uncontrolled cell growth caused by uncontrolled activation of the mTOR (46-48). The 
importance of this signaling axis in cancer is evident by the large degree of crosstalk with 
adjacent pathways (28,31,33,41,43,45). The p110α subunit contains a RAS-binding 
domain, which upon RAS-GTP binding augments PI3K/AKT activity under certain 
cellular conditions. Mutations in RAS lead to the persistence of the RAS-p110α 
interaction, resulting in the stabilization, and thus constitutive activation of the PI3K 
complex (28).  
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 PTEN loss of function, either through homozygous deletion, LOF mutation, or 
epigenetic silencing occurs in roughly 20% of all HNSCC (TCGA www.cbioportal.org) 
and has been shown to regulate AKT activation (46). Moreover, secondary PTEN loss 
has been shown to facilitate a more aggressive phenotype in HNSCC cells (42,47). Short 
hairpin RNA (shRNA) knockdown of PTEN in HNSCC cells results in decrease in cell 
adhesion, reduction in E-cadherin expression, and enhanced cell migration, all of which 
are characteristic of dedifferentiation and epithelial to mesenchymal transition (EMT) 
(47). PTEN loss more recently, has been shown to occur in distant metastasis in a patient 
with PIK3CA-driven breast cancer (42). All treatment refractory, secondary tumors in 
this patient that were resistant to BYL719, an alpha-specific PI3K inhibitor harbored a 
PTEN mutation, while other metastases that were drug responsive had wild type PTEN 
(42). These results were further confirmed in vitro using shRNAs against PTEN in 
BYL719-sensitive breast cancer cell lines, where PTEN loss led to BYL719 resistance 
(42).  
 AKT activation plays a role in tumor–induced angiogenesis through the 
interaction with the hypoxia-inducible factor 1-alpha (HIF-1α), and the vascular 
endothelial growth factor (VEGF) (28). Moreover, AKT is known to contribute to cancer 
cell immortalization through the indirect activation of nuclear factor kappa B (NFκB) and 
the sequestering of p53 through mouse double minute 2 homolog (MDM2) 
phosphorylation (41,48-50). Moreover, RAS signaling through the RAF/mitogen-
activated protein kinase kinase (MEK)/extracellular-signal-regulated kinase (ERK) 
pathway, as well as nutrient and oxygen sensing pathways (33) can also activate 
downstream mTOR leading to aberrant activation of key downstream components (51).     
1.3.2 PI3K/AKT Pathway and HPV 
 Activation of the PI3K/AKT pathway is also essential for the infection, 
maintenance, and progression of HPV, as well as other DNA viruses, in the host cell (31). 
Viral-mediated activation of the PI3K/AKT pathway helps circumvent stress-mediated 
inhibition of mTORC1 during HPV infection through favorable interactions with TSC1/2 
(31). Additionally, the viral oncoproteins E6 and E7 have been shown to interact with key 
members of the pathway: E7 can directly inhibit the action of protein phosphatase 2A 
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(PP2A), which modulates AKT signaling through the removal of phosphorylated residues 
at T308 and S473 (52,53). E6, conversely, binds to tuberin in the TSC1/2 complex and 
targets it for proteasomal degradation (54). Finally, constitutive maintenance of mTORC1 
activation will maintain active 5’ cap-dependent translation through the phosphorylation 
of the 4E-BP, which relieves the negative inhibition on the eIF4F complex, and the S6 
kinase (S6K), which phosphorylates S6 leading to the formation of translation initiation 
complexes (31,50,55). Taken together, a proposed feedback loop in which active HPV E6 
and E7 proteins promote PI3K/AKT signaling can be imagined. This would lead to and 
the constitutive activation of mTORC1, which in turn maintains 5’ cap-dependent 
translation of more E6 and E7 proteins to further abrogate cell cycling as well as insert 
into the host’s genome (31,56-58). 
1.3.3 PIK3CA 
 Through NGS efforts, PIK3CA has been identified as a key potential target in the 
treatment of HNSCC patients due to its high frequency of muation, its oncogenic nature 
as well as its amenability to being targeted by small molecule inhibitors (54). HNSCCs 
lack activating mutations in oncogenes, yet have high rates of mutations in tumor 
suppressors (6-11,TCGA www.cbioportal.org). Amongst the select few activating 
mutations, clinical targeting of these components in HNSCCs tends to present with great 
challenges.  
 Point mutations in the HRAS gene have also been identified in HNSCC, with 
roughly 5% of all tumors possessing mutations in hotspot residues (G12, G13, Q61) (6-
11,TCGA www.cbioportal.org). These mutations reduce GTPase activity, allowing 
HRAS to remain in the active state (6,11) in turn endowing the cell with cancer hallmarks 
(58,59). To date there are no successful strategies that effectively target RAS despite 
significant drug development efforts (65). This could be because of the lack of effective 
molecular compound-binding pockets on the surface of the protein, and the low affinities 
at which these compounds bind, which makes them incapable of competing with the high 
Ka of Ras and GTP (63). 
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 HPV-positive and HPV-negative tumors have activating PIK3CA point mutations 
in roughly 30% and 10% of tumors respectively (6-11). High incidences of PIK3CA 
mutations are also observed in HPV-positive cervical squamous cell carcinomas 
(61,TCGA, www.cbioportal.org), implying a viral preference for activation of the 
PI3K/AKT pathway, as discussed above.  
 The PIK3CA locus is located on chromosome 3 and can be mapped to position 
3q26.3 (22-25). It encodes the p110α catalytic subunit of the class 1A of the PI3K family 
(22-25). In normal physiology, p110α is found in complex with, and regulated by the p85 
subunit. It is composed of five domains: an adaptor binding domain (ABD), and a C2 
domain, which both interact with p85’s nSH2 domain, a RAS-binding domain (RBD), a 
helical, and a kinase domain (67). Upon activation, p110α phosphorylates PIP2 to its 
active PIP3, which binds to the PH domains of AKT and PDK1 and recruits them to the 
plasma membrane. AKT is then activated to induce canonical PI3K/AKT signaling 
(Figure 1) (26,31,41). Ninety percent of PIK3CA point mutations are found clustered at 
three hotspots: two missense mutations in exon 9, which alter amino acids 542 (E to K) 
and 545 (E to K) in the helical domain, and a missense mutation exon 20, which alters 
amino acid 1047 (H to R/L) in the kinase domain (44). Additional point mutations have 
also been identified in HNSCC, however their transforming capabilities are less potent 
than the three hotspot mutations (7,67). 
 Chang and colleagues were the first to show PIK3CA’s transforming ability by 
retrovirally transducing chicken embryonic fibroblasts (CEFs) with mutant PIK3CA, 
which lead to potent activation of downstream AKT targets (25). Furthermore, it was 
shown that mutant PIK3CA has the capacity to cause hemangiosarcomas in chickens 1 to 
2 weeks after retroviral infection (25). An independent study by Kang and colleagues 
showed similar findings with retroviral infection of CEFs with PIK3CA hotspot 
mutations; stable expression of hotspot PIK3CA mutants were able to cause aberrant cell 
growth and activation of downstream PIP3 and AKT. PIK3CA mutations also afford the 
cell the capabilities of anchorage independent growth (23), another hallmark of cancer 
generation (64). One study showed that retroviral infection of NIH-3T3 cells with E545K 
or H1047 mutants led to elevated lipid kinase activity through PIP3 and AKT activation 
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(22). Moreover, when these PIK3CA-mutant expressing NIH 3T3 cells were seeded onto 
soft agar, normally impermissible to cell growth, multiple colonies were formed. More 
recently, Okudela and colleagues demonstrated this same trend with immortalized airway 
epithelium 16HBE14o- cells. Retroviral transduction of cells with PIK3CA E545K and 
H1047R mutations lead to significant anchorage independent growth when plated on soft 
agar, and significantly increased trans-well migration, as compared to mock treated 
controls (68).   
 Studies examining the binding partners of helical and kinase p110α domain 
mutations have revealed key differences in their interactomes, specifically in the context 
of PI3K/AKT signaling (69). Zhao and Vogt determined that both the E542K and E545K 
mutations require an intact RAS-binding domain (RBD) and therefore RAS-binding to 
induce oncogenic transformation (69). Then again, dual helical/H1047R mutants are able 
to facilitate similar transforming capabilities suggesting that either kinase domain 
mutations, or RAS-E542/545/K activation of kinase activity accomplish similar results 
(69). This dependency on RAS or the H1047R mutation probably causes a 
conformational change at the substrate-binding site leading to active signaling (70,71). 
The H1047R kinase domain mutations are dependent on p85 binding, probably in part 
because the p85 subunit contacts the kinase domain affording proper protein folding 
confirmation (67,69).  
 Given that mutations in the helical domain are oncogenic (22-25,69,72) and result 
in similar activation of PI3Kα as kinase domain mutations, this suggests that the E542K 
and E545K mutations must have an impact on maintaining the kinase domain’s activity. 
The glutamate to lysine transition, which results in charge reversal from negative to 
positive, still permits p110α to be recruited to the plasma membrane (72). In fact, it is the 
C2 domain that seems to play a larger role in membrane localization (67). In the p85-
p110α complex, both the helical and kinase domain form the core of the complex, with 
the helical domain providing a bridge from the central C2 domain to the kinase domain 
(67). The 542 and 545 residues interact with the nSH2 domain of p85, which also 
contacts the kinase domain. Hotspot helical domain mutations may weaken p85 
regulation of p110α, thereby allowing oncogenic activity of the protein (67). Moreover, 
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helical domain oncogenecity is dependent on RAS binding (69); RAS binding can then 
alter the conformation of the kinase domain and activate signaling (70). Conversely, the 
H1047R kinase domain substitution appears to confer oncogenicity by a different 
mechanism, either by altering the conformation of the kinase activation loop, or 
increasing the binding affinity of p110α for the phosphatidylinositol substrate (22,29,43).    
 Given the propensity for both helical and kinase domain mutations to elicit 
oncogenicity, it can be postulated that both sets of mutations mitigate regulatory signals 
from the p85 subunit, while maintaining active kinase function.  
 The role that proto-oncogene amplification plays in the generation of a cancerous 
phenotype has been well documented (73). Amplification refers to an increase in gene 
copy number above the normal diploid number (74). Gene amplification has been 
observed as far back as 1978, when Alt and colleagues observed selective amplification 
of the dihydrofolate reductase (DHFR) gene in a subset of culture murine cells (75). 
DHFR results in the production of tetrahydrofolate, the active derivative of folate in 
humans, which is essential for rapidly dividing cells, i.e. cancer cells, in order to produce 
thymine (75).  
 Many studies have confirmed the high incidence of amplification in three families 
of protooncogenes implicated in cancer: MYC, ERBB2, and RAS (either KRAS, NRAS, or 
HRAS) (74). MYC amplifications are found at high frequencies in breast and ovarian, as 
well as in squamous cell carcinomas (76). Huw and colleagues reported that MYC 
amplification could mediate resistance to PI3K pathway inhibition (77). The best 
example of ERBB2 amplification is in breast cancers, where ERBB2 amplification is a 
predictive marker for poor prognosis and advanced stage, predicts response to HER2 
inhibition, and is found in 15-30% of all breast cancer tumors (78). In HNSCC, the 
ERBB-1 or EGFR gene is amplified in roughly about 10% of tumors and is an indicator 
of poor prognosis (9,79). Finally the RAS family is amplified sporadically across a large 
panel of cancers (74). 
 Amplification of PIK3CA occurs at a slightly greater frequency than PIK3CA 
point mutations in HNSCC. Multiple studies have reported high incidences of PIK3CA 
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amplification in both HPV-positive and negative HNSCC, with 28% incidence in HPV-
positive disease, and 21% in HPV-negative disease (6,7,TCGA www.cbioportal.com). 
PIK3CA amplification is also common in cervical cancers (TCGA: 
www.cbioportal.com), which further implies an additional link between HPV and 
PI3K/AKT signaling. Moreover, the ability of PIK3CA amplifications to drive oncogenic 
progression is supported by the fact that PIK3CA amplifications have been identified in 
pre-cancerous colorectal adenomas (80), as well as early gastric cancer lesions (81). 
PIK3CA amplification is also a marker for poor prognosis and treatment failure across 
multiple cancer types and treatment modalities (79,81-85). Importantly, PIK3CA 
amplification can give rise to the same oncogenic phenotype elicited by PIK3CA hotspot 
point mutations. Okudela and colleagues retrovirally transfected overexpressed wild type 
(WT) PIK3CA into the human bronchial epithelial cell line 16HBE14o-, and showed a 
significant enhancement in anchorage independent growth and cell migration, although to 
a lesser degree than activating PIK3CA hotspot point mutations (68). While PIK3CA 
amplification probably confers oncogenicity by a different means than PIK3CA point 
mutations, it can be reasoned that at the very least 3q26.3 chromosomal amplification 
plays a significant role in HNSCC oncogenesis.   
 The exact mechanism in which PIK3CA amplification drives oncogenesis has 
been challenged. Some suggest that certain proximal genes at the 3q.26.3 chromosomal 
region are the actual driver alterations (85). CNV analysis of oral squamous cell 
carcinoma (OSCC) have shown that specific regions of the 3q chromosome are amplified 
in more than half of tumors (10). Moreover, nearly half of all tumors also demonstrated 
gains of regions on the 3q chromosomal arm coupled with losses of regions on the 3p arm 
(10), which was more common in HPV-positive tumors (56). Multiple potential 
oncogenes are present near the 3q26 loci, particularly SOX2, (discussed below) TP63, 
TERC, RAB7A, and PRKCI (10). A recent review by our group outlines the roles of the 
last 4 genes in HNSCC mentioned above (Rizzo et al., Oral Disease 2014). 
 SOX2 (sex determing region Y box-2) has long been recognized as a key 
transcription factor in development and cancer, with an important function in the 
maintenance of pluripotency in undifferentiated stem cells (87,88). Studies have shown 
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that SOX2 is amplified in up to 21% of all HNSCC tumors (9,TCGA 
www.cbioportal.org). Similar findings have also been reported in other smoking-related 
malignancies such as lung (86) and esophageal squamous cell carcinomas (SCC) (87), as 
well as HPV-driven cervical cancers (TCGA). Importantly, SOX2 is proximal to the 
PIK3CA gene in the often-amplified 3q26 chromosomal region (9,10). Analysis of the 
most recent TCGA data on HNSCC (www.cbioportal.com) showed that the PIK3CA and 
SOX2 genes are both amplified in 21% of HNSCC patient tumors, with nearly 100% 
correlation. Multiple studies have shown an upregulation of SOX2 in cancer cells, 
including HNSCC stem cells (88), implicating SOX2 in EMT and metastasis (89,90). 
Moreover, SOX2 has been shown to impact PI3K, AKT, and mTORC1 signaling (89), 
while mediating resistance to pathway inhibition (90). Importantly, SOX2 amplification 
cannot singularly drive malignant transformation (85); considering the proximity and 
oncogenic abilities of PIK3CA, the two amplification events may work together to result 
in an aggressive cancer phenotype. 
 The functional consequences of PIK3CA aberration in HNSCC suggest an 
important role for this gene in cancer progression. Moreover, the strong interplay 
between HPV presence and PIK3CA would suggest an additional role for PIK3CA, or at 
least the PI3K/AKT pathway in viral function and progression to oncogenesis. More 
research is needed, which is outside the scope of this thesis. Nonetheless, the mode of 
action of PIK3CA point mutations and amplifications on clinical targeting is of great 
significance and merits significant attention.   
1.4 Clinical Targeting 
 Many head and neck cancer patients, especially those with oropharyngeal tumors 
are frequently treated with non-surgical techniques (91). In patients with locally advanced 
disease, the addition of platin-based chemotherapy to radiation improved local control as 
well as overall survival as compared to radiation therapy alone (91-96). Chemotherapy is 
not curative in HNSCC when given alone, but rather is used to sensitize cells to radiation 
as well as prevent distant metastasis (96). As such concurrent chemoradiation is the 
standard of care for locally advanced HNSCC based on several prospective studies (93-
95), while showing a more favorable response in HPV-positive HNSCC patients 
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(2,13,14). Despite moderate success, this treatment modality is associated with high 
toxicity as well as significant impacts on quality of life, irrespective of the burden of 
HNSCC disease alone. Moreover, in the case of HPV-positive HNSCC, patients tend to 
be younger (5) and more likely to survive the disease (2,13,14), leaving them to deal with 
the QOL burdens long after their treatments and cancer has subsided. It therefore 
becomes imperative to develop new therapies that not only maximize cure, as overall 
mortality rates are still roughly 50% (1,2,12,18), but also minimizes treatment and 
disease-associated morbidities. Targeted therapy of frequently mutated genes is an active 
area of clinical research and could provide a means for achieving these goals.   
1.4.1 Mechanisms of Resistance 
 It is unlikely that one treatment modality will be effective in all HNSCC patients. 
Moreover, even patients that meet the criteria for selected treatment (e.g. presence of 
mutation, no previous radio or chemotherapy) will vary in their respone to a given 
treatment (5,13,14). The advent of NGS has significantly improved our understanding of 
HNSCC biology in that it has identified key differences between HPV-positive and HPV-
negative disease, while elucidating the mutational characterization of both subtypes (6-
11, TCGA www.cbioportal.org). Importantly, it has identified a variety of molecular 
targets that may be amenable to targeted therapy (e.g. small molecule inhibitors or 
monoclonal antibodies). These agents have the potential to improve cure rates while 
reducing toxicity burdens associated with convential HNSCC treatments (1,2,12,18,96). 
Despite great potential, numerous studies have demonstrated drug resistence in a setting 
where cell lines and/or xenografts were expected to respond (42,57,77,101,103-109). In 
these cases, resistance is mediated through activation of secondary pathways (103,104), 
acquired secondary mutations downstream of the targeted gene product (42,106-108), or 
de novo mutations in the targeted gene (77,109). Moreover, the upregulation of P-
glycoprotein or multidrug-resistance (MDR)-associated proteins (MRP) expression, both 
ATP-binding cassette (ABC) transporter family, have long been known to drive 
resistance to many treatment modalities across many cancer subtypes (See ref 110 for a 
comprehensive review).  
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 It then becomes paramount to know the tumor’s mutational profile to explain 
resistance, and why observations are in discordance with initial hypothesis. As such, an 
appreciation of tumor evolution and the consequencial heterogeneity that it causes. The 
presence of convergent mutations could afford tumor cells phenotypic similarities but 
with distinct genotypes, and thus potentially different drug responses (111). It is the duty 
of clinicians and scientist to appreciate this evolutionary pattern and account for this 
heterogeneity by acquiring multiple biopsies from a patient tumor and properly 
identifying the oldest phylogenic driver mutation in these tumors (111).    
1.4.2 Cetuximab 
 Cetuximab is a monoclonal antibody against EGFR, a member of the homolog of 
the erythroblastic leukemia viral oncogenes (HER) family of receptors, with RTK 
function (91). In 2006, the FDA approaved the treatment of cetuximab with combination 
radiotherapy in HNSCC patients with locally or regionally advanced disease 
(www.cancer.gov). Bonner and colleagues determined that adjuvant cetuximab and 
radiation therapy compared to radiation alone, improved locoregional control in patients 
with advanced stage HNSCC (57). Cetuximab has also been approaved as a single agent 
for patients with recurrent or metastatic HNSCC who have previously failed platinum-
based therapy (National Cancer Institute, www.cancer.gov).   
 EGFR alterations are frequent in epithelial cancers, with HNSCC being no 
exception (57). Multiple studies have reported EGFR gene amplification in 
approximately 10% of all HNSCC (6,7,9-11, TCGA www.cbioportal.org), while being 
overexpressed in 80-90% of all HNSCC (79,112). However, in contrast to other cancers, 
particularly lung cancer, activating point mutations in EGFR are extremely rare (9, 
TCGA www.cbioportal.org). Cetuximab treatment has been shown to afford patients 
9.1% survival advantage at 5 years when used in combination with radiotherapy 
compared to radiotherapy alone (57), however these findings are underwhelming in 
comparison to response rates in other cancers (59). Amplification of the EGFR gene 
might explain this poor response, and could account for poor responses also observed 
with small molecule inhibtors against EGFR, particularly erlotinib and gefitinib (58,59).  
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1.4.3 PI3K/AKT pathway 
 The PI3K/AKT pathway and its spanning influence on multiple cellular pathways 
and processes, suggests that it is logical set of targets for the treatment of not just 
HNSCC, but also many other cancers. The presence of activating mutations in PIK3CA 
provides an avenue for targeted therapy in HNSCC, as it is far more practical to design 
inhibitors than to restore function to mutated tumor suppressors. Much of our preliminary 
understanding of PI3K inhibition comes from the Penicillium funiculosum metabolite 
Wortmannin, and the synthetic inhibitor LY294002, The former binds irreversibly, while 
the latter binds in a reversible manner (97). Both bind to the ATP binding pocket, like 
more recently developed PI3K inhibitors, however they are not isoform specific leading 
to a high toxicity that makes them inappropriate for clinical use (97). Nonetheless, they 
have provided a valuable template for the design of new generation PI3K inhibitors that 
are in clinical use today. 
 The lowest level of conservation among the PI3Ks occurs at a helix in the 
activation domain between residues 1032 and 1048 (27,67), thereby providing optimal 
avenues for drug specificity. Studies comparing p110γ and p110α provide insight into the 
oncogenic action of H1047R mutations; in p110γ the R1073 residue is equivalent to the 
H1047 residue in p110α (67). H1047 normally forms a hydrogen bond with the carbonyl 
oxygen of L956, something that does not occur at equivalent residues in p110γ. Instead, 
R1073 forms a hydrogen bond further along the helix, resulting in a shift in the activation 
loop structure (67). A similar change in residue interactions is thought to occur in 
H1047R PIK3CA mutations, thereby altering folding of the kinase domain (67).        
 Currently, the pan-isoform PI3K inhibitor BKM120 (Novartis) is the furthest 
along in development for the treatment of HNSCC. Ongoing Phase I and Phase II clinical 
studies have looked at BKM120 alone, and in combination with cetuximab with reported 
improved survival in patients with recurrent, metastatic or incurable, progressive HNSCC 
(41).  BEZ-235 (Novartis) is a dual mTOR/PI3K inhibitor, which has high affinity for the 
PI3K isoforms p110α (IC50=4nM), p110γ (IC50=5nM), and p110δ (IC50=7nM) (98). 
One study has shown that HNSCC cell lines harboring PIK3CA H1047R mutations are 
highly sensitive to BEZ235 compared to HNSCC cell lines with wild-type PIK3CA (7). 
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This data was confirmed in murine xenograft models using cell lines and patient-derived 
HPV-positive PIK3CA-mutated (E545K) tissue (7). Moreover, the combinatory treatment 
of BEZ235 and cetuximab was more effective than cetuximab alone in these models. It is 
important to note however that drugs that inhibit strictly the alpha subunit of PI3K have 
not been available until recently. Despite these encouraging findings, ongoing 
developments with BEZ235 have been stalled due to reformulation of the drug (99). 
Additionally two novel dual PI3K/mTOR inhibitors, the orally administered PF-502 and 
intravenously administered PF-384 (Pfeifer), have shown promising preliminary results 
(41,99), yet more research is needed. 
 A major drawback of pan-PI3K inhibitors however is whether a combination 
inhibitor can sufficiently target all cancer-driving mutations at levels that are not toxic to 
cell lines in vitro or, more importantly, in patients (114). The close link between PI3Ks 
and glucose homeostasis would imply that wide-spanning PI3K inhibition would induce 
hyperglycemia in patients, probably because of the overlapping roles PI3Ks, in this 
context PI3Kα and PI3Kβ, play in insulin signaling (40,102,114). This dependency is 
exemplified by studies where the pancreas and muscles of PTEN-deficient mice are 
protected against diet-induced insulin resistance (40,115-120). In the case of HNSCC, 
mutations in other members of the PI3K family are few (6,9,10,11,TCGA 
www.cbioportal.org), and therefore multi-targeted therapy seems redundant. Moreover, 
the low specificity of pan-PI3K inhibitors can cause inhibition of other vital cellular 
enzymes, particularly DNA-PK, essential for the repair of double stranded DNA breaks 
(120). Nevertheless the use of pan PI3K inhibitors in cancer treatment does have some 
merit: Castel and colleagues found that secondary BYL719-resistant breast tumors had a 
loss of heterozygosity (LOH) event in PTEN, which did not occur in the primary tumor 
(42,43,46,47). PTEN-deficient models have been shown to rely on p110β, rather than 
p110α (42), thereby implying a potential use for pan PI3K inhibition, or in this case 
combinatory p110α-β or p110β-specific inhibition in these tumors.     
 The AKT inhibitor MK-2206 (Merck) has shown promising effects when used 
concurrently with paclitaxel in preclinical and Phase I trials, and is currently being 
evaluated in Phase II trials as a single agent for recurrent metastatic HNSCC (100). 
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Rapamycin, as well as several analogs, have also shown promise in early clinical, as well 
as pre-clinical, models with regards to targeting mTOR (41). As mentioned previously, 
rapamycin only inhibits the mTORC1 complex, yet there are many drugs that inhibit both 
mTORC1 and mTORC2 complexes (31,99). A major problem in targeting both AKT and 
mTOR however is the negative feedback loop that ensues, whereby decreased AKT and 
mTOR signaling recycles RTKs, and the insulin receptor substrate 1 (IRS1) to the cell 
membrane.  This reactivates PI3K/AKT and adjacent pathway signaling, and leads to the 
reinstitution of cell growth (50). This observation stresses the need for the investigation 
and development of dual PIK3CA-mTOR inhibitors, or the implementation of 
combinatory use of PI3K and AKT or mTOR inhibitors.  
 The PI3K/AKT signaling axis is a very logical area to focus our attention for 
targeted therapies in HNSCC. This is based in the fact that PIK3CA, particularly in HPV-
positive cancers, has significantly higher mutation and amplification rates and can be 
targeted due to its oncogenic nature. Despite HRAS also being oncogenic and often 
mutated in HNSCC, understanding the complexities of this small GTPase and how to 
overcome its remarkable affinity for GTP remains an unresolved challenge. PIK3CA on 
the other hand, has such a fundamental role in cancer progression; being able to control 
this pathway as well as its upstream and downstream components may be the key to 
unlocking the proper treatments for HNSCC.           
1.4.4 BYL719 
 BYL719 (Novartis) is an orally adminstered PI3K inhibitor that strongly and 
selectively inhibits the gene product of PIK3CA, p110α. It preferentially binds to the 
p110α catalytic subunit and its hotspot mutations with a 50-fold smaller Kd, as compared 
to other PI3Ks, or mTOR (101). Moreover, its ability to potently inhibit AKT 
phosphorylation was also significantly better than either PI3Kβ or PI3Kδ isoforms (102).  
 BYL719, from the 2-aminothiazole classes of inhibitors (27), binds exclusively to 
p110α and its mutational derivatives with equal affinity (Kd ~4-5nM). The drug was 
designed to interact with PI3K p110α specific residues in the ATP binding pocket of the 
kinase domain (27,113). The primary amino group of BYL719 forms three hydrogen 
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bonds with PI3Kα residues, two of which are bidentate to the Q859 residues, which is 
only found in PI3Kα thereby providing the high degree of specificity (27). As a result of 
this hydrogen bonding, the BYL719-pyrrolidine moiety neatly resides in the catalytic 
pocket, which further explains the compounds high affinity for the p110α isoform (27).   
 In the case of pan-PI3K inhibitors, one of the greater areas of concern focuses on 
the high concentrations and therefore high toxicity required for effective therapeutic 
benefit (27,50,101,102,113,121). The rationale for the alpha-specific PI3K inhibitor 
BYL719 is that singular targeting of the key mutational event may not only be more 
effective, but will also minimize off target toxicity events, such hyperglycemia from 
insulin resistance, and weight loss (100-102,114,121). These same shortcomings are 
observed with dual PI3K-mTOR inhibitors, as the majority of these compounds inhibit 
the p110α, β, and δ isoforms, as well as mTORC1 and mTORC2 (99). In cancers where 
most of these targets aren’t mutated, it raises the questions as to whether doses required 
to inhibit the oncogenic isoform are attainable without unacceptable toxic effects (114). 
In terms of HNSCC, only PIK3CA point mutations and amplification occur in a 
significant subset of patient tumors (6-11).      
 Preliminary in vitro and xenograft studies with a panel of breast cancer lines and 
cell line-derived xenografts have shown BYL719 to be highly specific in targeting 
PIK3CA and inhibiting proliferation. Additionally, multiple groups have analyzed 
BYL179 drug response in a panel of cancer cell lines from the Cancer Cell Line 
Encyclopedia (CCLE), and found the best responses were observed in head and neck 
cancer and luminal breast cancer cell lines (97,100). In terms of safety profile, BYL719’s 
toxicity appears limited, with reversible hyperglycemia and mild GI discomfort reported 
as the only adverse effects (101,121). Additionally, it was found that the therapeutic 
index, the amount of drug required to produce 50% toxicity in a population over the 
minimum effective dose (122), was estimated to be 3.25 for BYL719, as compared to 1.1 
for a pan-PI3K inhibitor (101).   
 The primary focus of this thesis is to define which HNSCC genotype benefits most 
from BYL719 drug treatment. As such, the end goal is to be able to clearly define which 
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patients will respond and which patients will not in order to maximize efficacy of 
treatment.    
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1.5 Hypothesis and Specific Aims 
Hypothesis: HNSCC cell lines harboring PIK3CA point mutations and gene 
amplifications will be sensitive to BYL719, whereas cell lines lacking hotspot mutations 
or gene amplifications in PIK3CA will be more resistant to this inhibitor.  
Specific Aims: 
1) To determine rates of PIK3CA hotspot mutations and amplifications in a large 
cohort of HNSCC primary tumor samples   
2) To test the sensitivity of a panel of head and neck cell lines to the alpha-specific 
PI3K inhibitor BYL719  
3)  To measure the efficacy of BYL719 on tumor growth in cell line and patient-
derived murine xenografts 
4)  To determine the oncogenic dependency of HNSCC cell lines to key PI3K/AKT 
pathway components using siRNA knockdown, and determine if PIK3CA is the 
oncogenic driver in PIK3CA point mutant or amplified cell lines 
5)  To analyze the differences in BYL719 response in sensitive and resistant cell lines 
by analysis of the PI3K/AKT pathway 
6)  To determine and test combination drug therapies in BYL719 resistant cell lines 
according to the differences observed in Objective 4    
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2 MATERIALS AND METHODS 
2.1 Deparaffinization of Patient Samples 
 The formalin fixed paraffin embedded blocks from each patient’s primary tumor 
site were sectioned (5 µm thick) and mounted on slides. The slides were then 
deparaffinized with 3 minute washes in xylene (100%) twice, followed by a 1:1 xylene: 
ethanol mix, then ethanol (100%) twice, followed by single washes in ethanol at 95%, 
70% and 50%. Lastly, the slides were washed in water for 5 minutes. 
2.2 DNA extraction 
 Deparaffinized tissue was scraped into a 1.5 ml eppendorf tube containing 50–
100µl (depending on the amount of tissue) of TE and proteinase K (final concentration 2 
mg/ml) and incubated overnight at 65°C. Following proteinase K treatment, the samples 
were heated at 95°C for 10 minutes and allowed to cool to room temperature. Two 
hundred nanolitres of each sample was used directly in the qPCR reactions. 
2.3 Cell culture  
 Detroit562, JHU006, JHU011, JHU029, SCC4, SCC9, SCC15, SCC25, HMS001, 
93-VU-147T, UM-SCC47, UPCI:090, UPCI:154, PCI6A, PCI6B, PCI13, PCI22B, 
PCI30, RF15A, RF15B, RF22B, RF37A, RF37B, and FaDu cell lines were grown in 
Dulbecco’s Modified Eagle Medium with Ham’s F12 1:1 mixture (DMEM/F12) 
supplemented with 10% native fetal bovine serum (FBS), 1% penicillin/ streptomycin, 
and 2% hydrocortisone. The Cal33 cell line was grown in DMEM supplemented with 
10% heat inactivated FBS, 1% penicillin/ streptomycin, 1% L-glutamine, and 2% 
hydrocortisone. The HSC-2 cell line was grown in Roswell Park Memorial Institution 
(RPMI) media supplemented with 10% native FBS, 1% penicillin/ streptomycin, A 
summary of all cell lines used with their HPV, PIK3CA, and HRAS mutation/CNV status 
as well as the sources of all cell lines can be found in Table 1. 
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Table 1 Summary of HNSCC cell lines with HPV-status, PIK3CA hotspot mutation 
or amplification, PTEN loss, and HRAS hotspot mutation 
 
Cell line HPV status PIK3CA 
hotspot 
PIK3CA 
amplification 
HRAS 
hotspot 
Source 
Detroit562 Negative H1047R - - ATCC 
JHU006 Negative - - - John Hopkins  
JHU011 Negative - - - John Hopkins  
JHU029 Negative H1047L - - John Hopkins 
SCC4 Negative - - - ATCC 
SCC9 Negative - - - ATCC 
SCC15 Negative - Amplified - ATCC 
SCC25 Negative - Amplified - ATCC 
UM-SCC47 Positive - - - University of 
Michigan 
HMS001 Positive - Amplified - Harvard 
Medical School 
93-VU-147T Positive - Amplified - VU Medical 
Center 
UPCI:090 Positive - - - University of 
Pittsburg 
Cancer Institute 
UPCI:154 Positive - - - University of 
Pittsburg 
Cancer Institute 
PCI6A Negative E545K Amplified - UPMC 
PCI6B Negative - Amplified - UPMC 
PCI13 Negative - Amplified - UPMC 
PCI22B Negative - - - UPMC 
PCI30 Negative - Amplified - UPMC 
RF15A Negative - Amplified - University of 
Pittsburg 
Cancer Institute 
RF15B Negative - Amplified - University of 
Pittsburg 
Cancer Institute 
RF22B Negative - - G12V University of 
Pittsburg 
Cancer Institute 
RF37A Negative - - G12V University of 
Pittsburg 
Cancer Institute 
RF37B Negative - - G12V University of 
Pittsburg 
Cancer Institute 
FaDu Negative - Amplified - ATCC 
Cal27 Negative - - - Centre Antoine-
Lacassagne 
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Cal33 Negative H1047R - - Centre Antoine-
Lacassagne 
HSC2 Negative H1047R - - Tokyo Medical 
and Dental 
University 
ATCC denotes American Type Culture Collection 
UPMC denotes University of Pittsburg Medical Center 
RF denotes Dr. Robert Ferris, University of Pittsburg Cancer Institute 
 
2.4 STR profiling of HNSCC cell lines 
 All cell lines had 50ng of DNA extracted using the AllPrep DNA/RNA Kit 
(Qiagen Cat No 80204) according to the manufacturers protocol. Samples were sent to 
The Center for Applied Genetics (TCAG) in Toronto for short tandem repeat (STR) 
profiling. All HNSCC cell lines were compared to a reference genome in order to ensure 
proper identity.  
2.5 PIK3CA-hotspot mutational and PIK3CA, SOX2, PTEN 
CNV status, using real time-PCR 
2.5.1 PIK3CA hotspot mutations  
 Primers were designed for 4 specific PIK3CA mutations, E542K, E545K, H1047R, 
and H1047L, for real time-PCR analysis. Taqman probes and primer sequences are 
summarized in Table 2. E542K and E545K were conjugated to 6-carboxyl-X-rhodamine 
(ROX) fluorophores; H1047L and H1047R were conjugated to Carboxyfluorescein 
(FAM) fluorophores; and GAPDH, which served as the control, was conjugated to the 
Cy5 fluorophore. Experiments were performed in 96 well plates divided in half, so that 
E542K (ROX), H1047L (FAM), and GAPDH (Cy5) were detected in the first set of 
reactions, and E545K (ROX), H1047R (FAM), and GAPDH (Cy5) were detected in the 
second set of reactions.  
 PCR reactions (20µl) were prepared with 200ng of patient DNA, 10µl of 
Quantitech Multiplex PCR NoROX Master Mix (Qiagen), 7µl of water, 0.04µl of FAM 
probe, 0.04µl of ROX probe, 0.04µl of Cy5 probe, and 2.44µl of TE buffer (Invitrogen). 
0.04µl (0.24µl total volume of primer) of each forward and reverse primer sequences for 
the appropriate mutational analysis and GAPDH control were also added. PCR reactions 
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underwent a 15 minute denaturation step at 95°C, followed by 60 seconds at 94°C for 
annealing, and 90 seconds at 60°C for extension for 40 cycles.  
 Mutational analysis was performed in Excel, where ∆Ct was calculated according 
to the formula ∆Ct= Ct (sample) – Ct (GAPDH control). Mutations were detected by 
comparing ∆Ct of patient samples to the ∆Ct of known, previously sequenced controls. 
For E542K, patient 91 was used as a positive control; for H1047L, JHU029 was used as a 
positive control; for E545K, PCI6A was used as a positive control; and for H1047R, 
HSC2 was used as a positive control. Patient samples were removed from the study if 
their Cy5 (GAPDH) Ct score was greater than 35.0 after three replicates. It was deemed 
that these samples had insufficient DNA and therefore were excluded from the study. 
Seven HPV-positive samples were excluded from the study. All results were transcribed 
into the Oropharyngeal Cancer Patient (OCP) Database and checked for HPV status 
(Nichols et al, unpublished).         
Table 2 Taqman probe and primer sequence for RT-PCR 
Target Sequence (5’ to 3’) 
GAPDH 5’- [Cy5]TCTGCCCCCTCTGCTGATGCCCCCATGTTCGTCATGGGA[BHQ2 
F-GCTCATTTGCAGGGGGGAGCC 
R-CTGATGATCTTGAGGCTGTTG 
PIK3CA E542K 5’-[ROX]GCAATTTCTACACGAGATCCTCTC[BHQ2] 
F-GGGAAAATGACAAAGAACAGCTC 
R-CTTTCTCCTGCTCAGTGATTCT 
PIK3CA E545K 5’-[ROX]GCAATTTCTACACGAGATCCTCTC[BHQ2] 
F-GGGAAAATGACAAAGAACAGCTC 
R-ACTCCATAGAAAATCTTTCTCC 
PIK3CA H1047L 5’-[6FAM]GCAAGAGGCTTTGGAGTATT[BHQ1] 
F-CCCTAGCCTTAGATAAAACTGA 
R-TGTTGTCCAGCCACCATGCA 
PIK3CA H1047R 5’-[6FAM]GCAAGAGGCTTTGGAGTATT[BHQ1] 
F-CCCTAGCCTTAGATAAAACTGA 
R-TGTTGTCCAGCCACCTGCC 
F denotes forward primer sequence 
R denotes reverse primer sequence 
 
2.5.2 PIK3CA amplification 
 Primers to detect PIK3CA gene amplification have been described previously, and 
are summarized in Table 3. SYBR PCR reactions were performed in 96 well plates 
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divided into halves where one half detected TRAT1 controls, and the second half detected 
PIK3CA amplifications. TRAT1 and PIK3CA are located on opposite arms of 
chromosome 3, and TRAT1 was assayed in order to control for ploidy number, as the 
gene is found at an infrequently amplified locus on the 3p chromosomal arm (127). PCR 
reactions (15µl) were prepared with 200ng of either cell line, or patient DNA, 7.5ul of 
Power SYBR Green (2x) PCR Master Mix, 0.1ul of both Forward and Reverse PIK3CA 
or TRAT1 primers, and 7.1µl of water. PCR reactions were subjected to 10 mins of initial 
denaturation at 95°C, followed by 40 cycles of 30 secs of denaturation at 95°C, 60 secs of 
annealing at 55°C, and 60 secs of extension at 72°C.   
 Amplification analysis was performed in Excel, where ∆∆Ct was computed using 
the standard formula (123). Amplifications were detected by comparing ∆∆Ct of samples 
to ∆∆Ct of TCGA-defined controls. FaDu and SCC15 are amplified cell lines and were 
used as positive controls; 93-VU-147T has high levels of PIK3CA amplification and also 
served as a positive control, and Cal27 has been shown to have normal putative diploid 
gene copy number and served as a negative control (CCLE). All samples were 
normalized to the average of three germline controls taken from the blood of three 
different HNSCC patients in order to control for diploid copy number. Patient samples 
were removed from the study if their Ct score was greater than 35.0 as that sample was 
considered to have insufficient DNA. After 3 replicates, 4 HPV-negative patient samples 
were excluded from the study. All results were transcribed into the Oropharyngeal 
Cancer Patient (OCP) Database and checked for HPV status.     
2.5.3 PTEN CNV     
 PTEN PCR primers were designed to detect CNV, and are summarized in Table 3. 
SYBR PCR reactions (15µl) were prepared with 200ng of cell line DNA, 7.5µl of Power 
SYBR Green (2x) PCR Master Mix, 0.1µl of both Forward and Reverse of either 
GAPDH or PTEN primers, and 7.1µl of water. PCR reactions were subjected to 10 
minutess of initial denaturation at 95°C, followed by 40 cycles of 30 seconds of 
denaturation at 95°C, 60 seconds of annealing at 55°C, and 60 seconds of extension at 
72°C.    
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 CNV analysis was performed in Excel, where ∆∆Ct was computed using the 
standard formula (123). PTEN loss was detected by comparing the ∆∆Ct of cell lines to 
the ∆∆Ct of the PC3 prostate cancer cell line, which harbors a homozygous deletion at 
the PTEN locus (124). 
2.5.4 SOX2 amplification 
 Primers were designed for SOX2 and are described in Table 3. All reactions were 
performed in duplicate in a 96-well plate, divided in three. The first four columns (32 
wells) were used to detect TRAT1 status, the next four for PIK3CA amplification, and the 
final four for SOX2 amplification. PIK3CA amplification was assayed to confirm SOX2 
amplification, as the TCGA (www.cbioportal.com) reported nearly 100% co-
amplification of the two genes.  
 SYBR PCR reactions (15µl) were prepared with 200ng of cell line DNA, 7.5µl of 
Power SYBR Green (2x) PCR Master Mix, 0.1µl of both Forward and Reverse primers of 
TRAT1, PIK3CA, or SOX2, and 7.1µl of water. PCR reactions were subjected to 10 
minutess of initial denaturation at 95°C, followed by 40 cycles of 30 seconds of 
denaturation at 95°C, 60 seconds of annealing at 55°C, and 60 seconds of extension at 
72°C.   
 SOX2 amplification was computed in Excel in a similar fashion to PIK3CA 
amplification described above. FaDu, and SCC15 served as CCLE-defined positive 
controls, and Cal27 served as a CCLE-defined negative control. All cell lines were 
normalized to three germline controls from the blood of three different HNSCC patients. 
∆∆Ct was calculated using the formula previously described (98), and compared to 
PIK3CA amplification.   
Table 3 Primer sequences for SYBR RT-PCR 
Target Sequence (5’ to 3’) 
PTEN F-CATTATAAAGATTCAGGCAATG 
R-GACAGTAAGATACAGTCTATC 
PIK3CA amplification F-CATTTGCTCCAAACTGACCA 
R-AGAGATTGGCATGCTGTCGA 
TRAT1 F-CATGTCAGGTAAGTGGCATT 
R-GGGTCTTCTCGTTAGGACTTAG 
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SOX2 F-CACATGAAGGAGCACCCGGATTAT 
R-GTTCATGTGCGCGTAACTGTCCAT 
GAPDH F-GCTCATTTGCAGGGGGGAGCC 
R-CTGATGATCTTGAGGCTGTTG 
F denotes forward primer sequence 
R denotes reverse primer sequence 
 
2.6 Drug treatments and determination of cell viability  
 Cells were seeded at a density of 1.0-2.0x104 cells/well (20-40% confluency) in 96-
well dishes. BYL719 was resuspended in dimethyl sulfoxide (DMSO) in order to achieve 
a 11.4mM stock concentration, and rapamycin was resuspended in DMSO to achieve a 
stock concentration of 10mM. The following day, cells were treated with escalating doses 
of BYL719 (0.5µM-8µM), or rapamycin (0.01µM-10µM). A well was left untreated 
(normal growth media), and another was treated with 0.09% DMSO to act as negative 
controls. Cells were incubated at 37°C with 5% carbon dioxide (CO2) until needed. At 48, 
72, 96, and 120 hours, cells were subjected to 10µl of PrestoBlueTM Cell Viability 
Reagent (Invitrogen) and incubated at 37°C with 5% CO2 for 30 minutes. PrestoBlueTM 
detects cell viability by capitalizing on the fact that viable cells maintain a reducing 
environment in their cytosols. The resazurin-based solution contains a cell-permeable 
compound that is blue with minimal fluorescence. Upon entry to the cytosol of viable 
cells, that compound is reduced to fluorescent red compound which can be detected. Cell 
viability was measured by fluorescence using the Wallac Victor2 1426 Multilabel 
Counter with an excitation wavelength of 535 nanometers (nm) (25nm bandwidth) and an 
emission wavelength of 615nm (10nm bandwidth). 
2.7 Determination of the half maximal inhibitory 
concentration (IC50)        
  Decrease in cell viability was quantified using Excel and normalized to DMSO-
treated controls in order to determine the half maximal drug concentration, IC50. This is 
defined at the drug concentration required to inhibit 50% of cell growth. The upper limit 
of the dose range was 8µM, and therefore cell lines that did not reach an IC50 were not 
given an experimental value for BYL719 response. IC50 was determined in two ways: 
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first, using the growth curves, the dose at which the curve reached 50% decrease in cell 
viability was determined on the x-axis. Second, non-linear regression was also performed 
in order to ascribe a predicted IC50 for cell lines that responded outside the dose range of 
this study. 
2.8 Non-Linear regression 
 Non-linear regression was performed in Graphpad Prism in order to ascribe IC50 
values to cell lines that didn’t reach a decrease of 50% cell viability at our highest dose 
used. Scatterplots were generated in Graphpad Prism, and a line of best fit was generated 
for the data points. Since most curves did not experience a linear response to BYL719, 
we chose non-linear regression for our analysis. An equation was generated using the 
function in Excel in the form of Y=Ae-bx, where y is the proportion of cell viability (in 
our case we are looking at a 50% decrease in cell viability, so 0.5), A is the initial cell 
viability, b is the coefficient denoting decrease in cell viability (decay coefficient), and x 
is the drug concentration required to achieve ‘y’. In order to compute a predicted IC50, the 
y value was denoted as 0.5 (for 50% decrease in cell viability), and the equation was 
solved for x.   
2.9 Determination of effective combinatory rapamycin dose 
 In order to determine the effective concentration of rapamycin to use in 
combinatory treatment with BYL719, the
 
half maximal drug concentration of rapamycin 
was determined in a subset of HNSCC cell lines. Foue PIK3CA-amplified or point-
mutated cell lines (PCI6A, FaDu, 93-VU-147T, and Cal33 see Table 1) were selected in 
order to perform this study. Cell lines were treated with escalading doses of rapamycin 
(10µM, 20µM, 30µM, 40µM, and 50µM) and allowed to incubate for 72h at 37°C with 
5% CO2. At 72 and 96 hours, cells were assayed for cell viability as previously described. 
The IC50 for the 4 cell lines was determined by methods described above (Materials and 
Methods 2.7). Previous studies, specifically using rapamycin, have deemed 20% IC50 as 
an appropriate starting point for drug combination synergy (125,126). Three of the four 
cell lines tested had a rapamycin IC50 between 30-40µM (FaDu was >50µM). Therefore, 
6µM (20% of 30µM) was deemed appropriate for initial combination therapy studies. 
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2.10 Western blotting 
 Cells were washed with ice cold PBS and either scraped and collected into 1.5ml 
Eppendorf tubes, or incubated for 5 minutes on ice in their respective wells with ice-cold 
0.5% NP40 Lysis Buffer (0.5% NP-40, 150mM NaCl, 50mM Tris-HCl pH 7.8) 
supplemented with 0.5% protease inhibitor cocktail (Sigma). Cells collected by scraping 
were centrifuged at 1000 rpms for 5 minutes in order to pellet the cells, followed by the 
addition of 75-100µl 0.5% NP40 Lysis Buffer supplemented with 0.5% protease inhibitor 
cocktail. Lysates were cleared by centrifugation at 10,000 rpm for 10 minutes at 4°C. 
Total protein concentration was measured by a modified Bradford assay (Invitrogen). 
Five micrograms of whole cell lysate was resolved on NuPage 4-12% continuous 
gradient bis-tris gels (Life Technologies) at 200V for one hour. Resolved proteins were 
transferred onto polyvinylidene fluoride (PVDF) (GE Healthcare) membranes using a wet 
transfer method at 1.1h at 20V with a limit of 25 A/membrane.  
 Membranes were blocked in either 5% BSA in tris-buffered saline (TBS)-Tween 
(TBST), or 5% nonfat dry milk in TBST for one hour at room temperature rocking 
according to the manufacturers guidelines or recommendations. Primary antibody 
(diluted in either 5% BSA-TBST for phospho-proteins, or 5% nonfat dry milk in TBST 
for detection of proteins independent of phosphorylation status) was placed on the 
membrane and allowed to incubate overnight at 4°C with rocking. A list of the primary 
antibodies and their working concentrations can be found in Table 4.  
 The following day, membranes were washed 3 times with TBST for 10 minutes. 
Secondary antibodies against either mice or rabbits where raised in goats and the 
resulting secondary antibodies were conjugated to horseradish peroxidase (HRP) (1:5000 
GαM (Jackson Research Labs), or 1:2000 GαR (Jackson Research Labs)). Secondary 
antibodies were diluted in 5% nonfat dry milk-TBST and placed on the membranes and 
rocked at room temperature for 30 minutes. Protein- antibody complexes were detected 
using chemiluminescence with Luminata Crescendo Western HRP Substrate (Millipore) 
and resolved on Amersham Hyperfilm ECL (GE healthcare) or using the ChemoDoc Gel 
Imager (BioRad). Β-Actin, α-Tubulin, eIF4E and/or Rab11 were used as loading controls.  
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Table 4 Comprehensive list of all primary antibodies used in this thesis 
Antibody  Target Dilution Dilution 
Media 
Company Secondary 
antibody 
PIK3CA PIK3CA 1:1000 5% BSA-TBST Cell Signaling 
Technology 
GαR (1:2000) 
AKT AKT 1:1000 5% Milk-TBST Cell Signaling 
Technology 
GαR (1:2000) 
Phospho-AKT p-AKT 
(Thr308) 
1:1000 5% BSA-TBST Cell Signaling 
Technology 
GαR (1:2000) 
Phospho-AKT p-AKT 
(Ser473) 
1:2000 5% BSA-TBST Cell Signaling 
Technology 
GαR (1:2000) 
mTOR mTOR 1:1000 5% Milk-TBST Cell Signaling 
Technology 
GαR (1:2000) 
Phospho-
mTOR 
p-mTOR 1:1000 5% BSA-TBST Cell Signaling 
Technology 
GαR (1:2000) 
Pathscan #1 p90RSK, p-
AKT, p-
ERK1/2, p-S6 
(235/6), 
Rab11 
1:200 5% BSA-TBST Cell Signaling 
Technology 
GαR (1:2000) 
Pathscan #2 p-p90RSK, p-
p53, p-p38 
MAPK, p-S6 
(235/6), eIF4E 
1:200 5% BSA-TBST Cell Signaling 
Technology 
GαR (1:2000) 
PTEN PTEN 1:2000 5% BSA-TBST Cell Signaling 
Technology 
GαR (1:2000) 
Phospho-
PTEN 
p-PTEN 
(Ser380/ 
Thr382/383) 
1:1000 5% BSA-TBST Cell Signaling 
Technology 
GαR (1:2000) 
Β-Actin Β-Actin 1:5000 5% Milk-TBST Cell Signaling 
Technology 
GαR (1:2000) 
α-Tubulin α-Tubulin 1:2000 5% Milk-TBST Sigma GαM (1:5000) 
 
2.11 Combination therapy of rapamycin and BYL719 
 Cells were plated into 96-well plates as described previously, and in 6-well plates at 
1.0x105 cells/well to achieve 50% confluency the next day. Stock solutions of 6µM 
rapamycin, 10µM BYL719 with either 6µM or 30µM of rapamycin, and 10µM of 
BYL719 were prepared in the appropriate media. Eight cell lines, all resistant to singular 
BYL719 treatment, were used for this study. Their mutational profiles can be found in 
Table 1. 
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 In the 96-well plates, cells were subjected to increasing doses of BYL719 (1µM, 
2.5µM, 5µM, 7.5µM, and 10µM) at a constant rapamycin concentration of 6µM. A 
DMSO-treated control was administered in the first row of every plate. A second plate 
was also treated in parallel with identical dosage of BYL719 to serve for comparisons 
sake. Cells were incubated at 37°C with 5% CO2 for 72 and 96 hours before cell viability 
using PrestoBlueTM Cell Viability Reagent (Invitrogen) was used to determine cell 
viability, as previously described above. Half maximal inhibitory concentrations (IC50) 
for each cell line were determined as previously described, and BYL719 alone and 
BYL719 +6µM rapamycin were compared.     
 In the 6-well plates, cells were subjected to 8 different drug combination 
treatments: either BYL719 alone at 0µM (DMSO-treated control), 1µM, 5µM, or 10µM, 
or identical BYL719 concentrations but with 6µM of rapamycin. Cells were allowed to 
incubate at 37°C with 5% CO2 for 36h, which was determined experimentally to be the 
timepoint at which AKT phosphorylation decreased considerably, then collected by cell 
scraping as described above. A Western blot was performed for each cell line (as 
described above) and each membrane was blotted for p-S6 (S235/6) (Pathscan #1, or #2), 
p-AKT (T308), p-AKT (Ser473) (Pathscan #1), and AKT (Table 2). Rab11 (Pathscan #1) 
or eIF4E (Pathscan #2) served as a loading control.  
2.12 Densitometry 
 In order to determine the effects of BYL719, rapamycin, and BYL719-rapamcyin 
combination, densitometry was performed using ImageJ to quantify S6, and AKT 
phosphorylation. The pS6 band at 32kDa, and the Rab11 band at 25kDa for each dose 
were boxed using the ‘box tool’ in order to generate densitometry graphs. Background 
signal was eliminated using the ‘line tool’ and values were generated and exported to 
Excel for analysis. Densitometry readings for S6 phosphorylation were first normalized 
to their corresponding Rab11 loading controls, then normalized to the difference of the 
untreated control. S6 phosphorylation decrease was graphed as a percentage of the 
untreated controls.   
 ImageJ was also used to determine the effects of BYL719 on phospho-AKT levels 
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at Serine 473. Excel was also used for this analysis. Phospho-AKT levels were first 
normalized to endogenous AKT for each cell lines. This value was then normalized to the 
untreated control and multiplied by 100 in order to generate an AKT phosphorylation 
percentage for 5µM BYL719 treatment. Phospho-AKT (Ser473) was graphed as a 
percentage of the untreated controls.  
2.13 siRNA study for oncogenic dependency 
 Cal33, Detroit562, PCI6A, and FaDu were selected in order to analyze whether 
siRNA knockdown of key PI3K/AKT signaling components in cells with PIK3CA 
mutations (Cal33 and Detroit562), amplifications (FaDu), or both (PCI6A) resulted in 
decreased cell viability. Cells were plated in a 60mm dish at a density of 5.6x105 
cells/well in order to achieve 50% confluence the next day. We ordered a panel of 
siRNAs against different components of the PI3K/AKT signaling axis from ABM Good 
in order to analyze the effects of knockdown on cell viability: Two AKT siRNAs (cat. 
nos. 659 and 660), two mTOR siRNAs (cat nos. 603 and 604), and two PIK3CA (cat nos. 
20 and 22). Seven and a half microlitres of siLentFect (Bio-Rad) in 250µl of serum-free 
media (SFM), and 20nM of siRNA into 250µl of SFM was added to cells in 2.5ml of 
fresh, complete media as suggested by the BioRad Protocol. Briefly, 250µl of siRNA-
SFM mixture was added to the 250µl siLentFect-SFM mixture, vigorously mixed, and 
allowed to incubate at room temperature for 20 minutes in order to allow proper 
conjugation of siRNA and siLentFect for effective intracelluarization. siRNA-siLentFect-
SFM mixture was then added to 60mm dishes, rocked back and forth to ensure mixing, 
and incubated at 37°C with 5% CO2 overnight. Twenty-four hours later, cells were 
trypsinized and placed equally into a 96 well dish. Presto Blue Reagent was administered 
to the wells at 48, 72, 96, and 120h after transfection.  
2.14 Animals 
 NOD/SCID/IL2-receptor-γ (NSG) mice were bred internally at the OCI Animal 
Care facility and ranged from 4-6 weeks old. All animals were kept in a pathogen free 
environment on a standard 12h day/12h night cycle and were fed a standard sterilized 
pellet diet and water ad libum. Animals were treated under the ethical guidelines of the 
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Animal Care Committee at the OCI Animal Care Facility. 
2.15 Generation of drug treatment dose and schedule 
 In vivo BYL719 dosing levels and scheduling were determined using cell line-
derived xenografts. A cell line-derived xenograft was generated by injecting 107 cells of a 
moderately sensitive (blue-shading in Figure 4A) cell line into the flanks of NSG mice in 
a volume of 100µl cell culture media and matrigel (1:1). Approximately 20 mice were 
then treated with placebo (2 mice) and increasing doses of BYL719 (2 mice per dose) by 
oral gavage. In this manner, a reasonable dose and schedule was established for further 
xenograft (cell line and patient-dervied) studies.  
2.16 Generation of cell line-derived NSG mouse xenografts 
 This protocol was designed by our group, but was performed at the University of 
Toronto in Dr. Laurie Ailles’ lab. Cal33 and 93-VU-147T cell lines were selected for in 
vivo xenograft studies with NSG mice. Cal33 cells were chosen because they were the 
most sensitive of all PIK3CA-mutant cell lines; 93-VU-147T cells were chosen because 
they are HPV-positive, harbor the highest degree of PIK3CA amplification (Figure 2), 
and were also highly resistant to BYL719 (Figure 4A). 107 cells of either Cal33 or 93-
VU-147T in a volume of 100µl cell culture media and matrigel (1:1) were injected into 
the flank of NSG mice. Animals were randomized into one of three groups (n=5): corn oil 
control, 25mg/kg of BYL719, or 50mg/kg of BYL719. Tumors were allowed to grow 
until they reached a volume of 200mm3, roughly 2 weeks after injections. At this volume, 
it was experimentally determined by Dr. Ailles that the tumors underwent log phase 
growth, which proved to be the ideal time point for drug delivery. Tumor volume was 
measured every other day with digital calipers and tumor volume was calculated by the 
formula Volume= (Length x Width2) x 0.52. BYL719 was given daily by oral gavage. 
Corn oil was used because it soluabilized BYL719. The endpoint of this study occurred 
on Day 26 when tumor diameters reached the maximum allowable size of 1.5cm (Animal 
Care Committee) in the control group mice. Mice were euthanized according to the 
ethical guidelines of the Animal Care Committee at the OCI Animal Care Facility.  
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2.17 Handling of fresh tumor specimens for xenograft 
generation   
 Tumor specimens were obtained either by cupped biopsy at the time of diagnosis or 
taken from the center of the resection specimen at the time of surgical management. A 
pathologist confirmed the presence of invasive SCC on a portion of the sample by frozen 
section. Tumor samples were then placed on ice and shipped overnight to the Animal 
Care Facility at the Ontario Institute for Cancer Research (OICR).  
2.18 Tissue processing, implantation and tumor molecular 
characterization  
 Tumor tissue was cut into small pieces of ~1x1 mm using a sterile surgical blade. 
One representative piece was to be frozen at −80oC for further molecular and 
pathological analysis. As soon as possible (ideally within 24 h), pieces were implanted 
subcutaneous in the flanks of 5 NSG mice. Once palpable, tumors were measured twice 
weekly until a maximum diameter of 1.5 cm was reached over the course of 2-6 months. 
The tumors were then surgically removed and representative pieces were preserved in 
various fixatives for additional analysis. Hematoxylin and eosin (H&E) slides were made 
from formalin-fixed, paraformaldehyde embedded (FFPE) blocks in order to follow any 
changes in morphology and to confirm the epithelial nature of the tumor. DNA was 
extracted from the original patient’s blood, and DNA and RNA was extracted from a 
small portion (3x3 mm) of the first pass tumor. The rest of the tumor was sectioned into 
1x1 mm pieces, and then re-implanted subcutaneously in a new generation of mice. This 
process was repeated for every passage. Tumors are considered engrafted if they are 
passaged at least once in vivo. Tumours are considered engraftment failures if tumour 
growth is not detected by the sixth month after implantation. Note that subsequent 
passages are of high efficiency, in that >90% of tumours engraft and up to 20 mice can 
easily be implanted from a single PDX tumour. 
2.19 Generation of patient-derived NSG mouse xenograft 
 This protocol was designed by our group, but was performed at the University of 
Toronto in Dr. Laurie Ailes’ lab. Patient tumors were implanted into the flank of NGS 
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mice and allowed to grow until palpable. Mice were divided into two groups of 5 and 
given one of two treatments, corn oil control, or 50 mg/kg BYL719. Once tumors were 
palpable (on day 28), BYL719 was administered 5-days/ week by oral gavage. Tumor 
volume was measured every other day with digital calipers and tumor volume was 
calculated by the formula Volume= (Length x Width2) x 0.52. The endpoint of this study 
occurred on Day 48 when tumor diameters reached the maximum allowable size of 1.5cm 
(Animal Care Committee) in the control group mice, and all animals were euthanized 
according to the guidelines set forth by Animal Care Committee. Tumor volume was 
weighed at the end of the study in order to assess size. 
2.20 Statistics 
 The data was analyzed in SigmaStat. Comparison of HPV-positive and HPV-
negative tumors’ PIK3CA mutational data was analyzed using a Fisher’s Exact test. All 
IC50 comparisons, phospho-S6 levels, and phospho-AKT levels were analyzed using a 
Student’s T-test. Short hairpin RNA as well as combination drug therapy response was 
analyzed using a One-way analysis of variance (ANOVA) with a Tukey’s range test. P 
values less than 0.05 were considered significant (* <0.05). 
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3 RESULTS 
3.1 PIK3CA hotspot point mutations and amplifications 
occur in a significant proportion of HNSCC tumors, with a 
proportion of tumors harboring both PIK3CA hotspot 
mutations and amplifications 
 Multiple NGS studies have confirmed the high incidence of both PIK3CA hotspot 
mutations (E542K, E545K, H1047R) and gene amplifications in HNSCC tumors (6,9-
11,TCGA www.cbioportal.org). Therefore, we sought to determine whether similar 
frequencies would be observed in HNSCC patient tumor DNA taken from the London 
Regional Cancer Program (LRCP) tumorbank. Fresh patient samples were prepared as 
described above and stored at -80°C. If a patient sample had a threshold value (Ct) above 
35.0 for its control (either TRAT1 (amplification) or GAPDH (mutation)), the sample was 
deemed to have poor DNA content and was discarded from the study. After three 
experimental repeats of 191 oropharyngeal patient samples, 8 were excluded from the 
mutational analysis, and 5 from the amplification analysis. No non-oropharyngeal patient 
samples were excluded from the study.   
 One hundred and eighty-three patient oropharyngeal tumor, and 89 patient non-
oropharyngeal HNSCC tumors DNA samples were subjected to real time-PCR analysis 
for mutation detection as described above. Four different point mutations were sought 
out: E542K, E545K, H1047L, and H1047R. Indeed, PIK3CA mutational rates determined 
agreed with those previously reported (6,7,9-11,TCGA www.cbioportal.org) with an 
overall mutation rate of 17.5%, with significantly higher point mutational rates in HPV-
positive oropharyngeal tumors (28.2% in HPV-positive, compared to 8.2% in HPV-
negative) (P<0.05) (Table 5). Non-oropharyngeal tumors had significantly lower 
incidence of PIK3CA mutations (4.4%) as compared to oropharyngeal tumors (P<0.05) 
(Table 6).  
 For PIK3CA gene amplification, oropharyngeal samples were tested using SYBR 
Green real time-PCR described above. One hundred and eighty-six patient samples were 
tested. The TRAT1 gene, found on the 3p chromosome, (127), was used as a control for 
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Table 5 PIK3CA hotspot mutation frequencies in oropharyngeal patient samples 
from LRCP tumorbank. Real time-PCR results revealed high PIK3CA hotspot 
mutational rates in oropharyngeal tumors from the LRCP tumobank. Bracketed numbers 
denote the number of tumors that had PIK3CA mutations. N=183 (N=85 HPV-positive, 
N=98 HPV-negative), *Denotes statistical significance between HPV-positive and HPV-
negative PIK3CA mutation rates according to a Fisher’s Exact Test  (P<0.05) 
PIK3CA status HPV-positive HPV-negative Total 
N 85 98 183 
E542K 7% (8) 3.1% (3) 6% (11) 
E545K 15.3% (13) 5.1 %(5) 9.8% (18) 
H1047L 0 0 0 
H1047R 3.5% (3) 0 1.6% (3) 
Overall 28.2% (24)* 8.2% (8) 17.5% (32) 
 
Table 6 PIK3CA hotspot mutation frequencies in non-oropharyngeal patient 
samples from LRCP tumor databank. Real time-PCR results revealed lower PIK3CA 
hotspot point mutational rates in non-oropharyngeal HNSCC tumors from the LRCP 
tumorbank compared to oropharyngeal tumors. Bracketed numbers denote the number of 
tumors that had PIK3CA mutations N=89 *Denotes statistical significance of PIK3CA 
mutations from oropharyngeal tumor rates (p<0.05) 
PIK3CA status Total 
N 89 
E542K 1.1% (1) 
E545K 2.2% (2) 
H1047L 0 
H1047R 1.1 (1%) 
Overall 4.4% (4)* 
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the relative diploid number, and was used to standardize PIK3CA amplification to normal 
diploid 3q chromosome levels. The results suggested that PIK3CA amplification occurs at 
high frequencies in both HPV-positive and negative oropharyngeal tumors (Table 7), 
which correlated with the current literature (7,TCGA www.cbioportal.com) (HPV-
positive 47.8%, HPV-negative 33%), despite our gene amplification rates being higher. 
Much like with hotspot point mutational analysis, PIK3CA amplification occurs at a 
higher frequency in HPV-positive oropharyngeal tumors compared to HPV-negative 
oropharyngeal tumors, yet this difference was not significant (p=0.052) (Table 7).   
 We next sought to determine the number of oropharyngeal patient tumors that 
harbored both PIK3CA hotpot mutations and amplifications. All patient samples that 
were excluded due to insufficient DNA did not have a PIK3CA point mutation or 
amplification. Fourty percent of all patient tumors that had PIK3CA point mutations also 
had PIK3CA amplifications, with more HPV-positive tumors (45.8%) having both events 
compared to HPV-negative tumors (27.3%) (Table 8). HPV-positive tumors with helical 
domain mutations both had 5 tumors with PIK3CA gene amplification (E542K 5/8, and 
E545K 5/13), whereas HPV-positive H1047R mutant tumors only had one (1/3) (Table 
8). Conversely, only HPV-negative tumors with E545K mutations showed co-
amplification of the PIK3CA gene (E545K 3/5, E542K and H1047R both 0/3) (Table 8). 
In both types of HNSCC, dual mutational events were almost equally frequent in both 
helical domain point mutations (E542K 5/11, E545K 8/18) and much less common in 
tumors with H1047R point mutations (1/6) (Table 8). Whether mutiple mutations in the 
PIK3CA gene results in a different phenotype than singular PIK3CA point mutation or 
amplification remains to be determined. 
3.2 PIK3CA amplification occurred in a subset of HNSCC 
cell lines, whereas PTEN loss did not 
 Eleven of the 28 HNSCC cell lines, two being HPV-positive (93-VU-147 and 
HMS001) had at least one extra copy of PIK3CA relative to the control gene (Figure  
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Table 7 PIK3CA amplification frequencies in oropharyngeal patient samples from 
LRCP tumorbank. Real-PCR results revealed PIK3CA amplification rates from 
oropharyngeal tumors from the LRCP tumor databank agreed with the amplification rates 
reported in current NGS literature. N=183 (N=85 HPV-positive, N=98 HPV-negative). 
Statistical analysis using a Fisher’s Exact Test revealed that the difference between HPV-
positive and HPV-negative amplification rates approached significance (P=0.052) 
PIK3CA status HPV-positive HPV-negative Total 
N 92 94 186 
Amplification 47.8% (44) 33% (31) 40.3% (75) 
 
Table 8 PIK3CA hotspot mutation and amplification frequencies in oropharyngeal 
patient samples from LCRP tumorbank. Real time-PCR results revealed that dual 
PIK3CA point mutations and gene amplification occur in oropharyngeal tumors. 
PIK3CA status HPV-positive HPV-negative Total 
Amp/ E542K 62.5% 
(5/8) 
0/3 45.4% 
(5/11) 
Amp/ R545K 38.5% 
(5/13) 
60% 
(3/5) 
44.4% 
(8/18) 
Amp/ H1047R 33.3% 
(1/3) 
0/3 16.7% 
(1/6) 
Overall 45.8% 
(11/24) 
3/11 
(27.3%) 
40% 
(14/35) 
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2A,B). This finding was relevant because it provided us with representation of PIK3CA 
amplification for BYL719 testing. Moreover, we also identified one cell line that had 
both a PIK3CA hotspot mutation (E545K) and gene amplification (PCI6A). Considering 
the amount of tumors with co-insult events, the PCI6A cell line afforded us a model to 
determine the sensitivity of these tumors to BYL719.   
  In normal physiology, PTEN antagonizes the action of PI3Kα signaling (39), and 
latent, secondary mutations in PTEN have been shown to facilitate a more aggressive 
phenotype, as well as mediate BYL719 resistance (42,47), I therefore sought to 
characterize PTEN status in all our HNSCC cell lines. The PC3 cell line has been 
reported to have a homozygous deletion at the PTEN locus (124) and was therefore used 
as the positive control for PTEN loss. None of the HNSCC cell lines used in this study 
harbored homozygous PTEN deletions (Figure 3A,B).      
3.3 PIK3CA hotspot mutant cell lines are significantly more 
sensitive to BYL719 than both PIK3CA-amplified and 
PIK3CA-non-hotspot mutant cell lines 
 Twenty-eight cell lines were treated with increasing doses of BYL719, and 
sensitivity was determined by calculating the half maximal inhibitory concentration 
(IC50). A cell line was deemed sensitive if it responded to BYL719 at a dose below 2µM 
because above this concentration BYL719 begins affecting the other PI3K isoforms 
(105). The upper range of our study was 8µM. If a cell line did not experience a 50% 
decrease in cell viability at this dosage, it was deemed resistant and grouped into the red-
shaded area of Figure 4A. Non-linear regression was performed in order to ascribe a 
predicted-IC50 for cell lines outside the dosage limit and allow proper statistical analysis 
(Figures 4B,C,D).  
 Contrary to our initial hypothesis, only cell lines that harbored H1047R PIK3CA-
hotspot mutations (Detroit562, Cal33, and HSC2) were sensitive to BYL719 treatment 
(2.06+/-2.40 µM, green shading in Figure 4A), which was significantly different from 
PIK3CA amplified (P=0.003), and PIK3CA non-hotspot (P=0.011) cell lines (Figures 4A, 
B, D). The JHU029 cell line, which harbors a non-conventional H1047L PIK3CA  
 A 
B 
Figure 2 PIK3CA amplification status in HNSCC cell lines. 
performed as described above on HNSCC cell lines in order to determine CNV of the 
PIK3CA gene. The CCLE had previously characterized 
number arrays.  This information was used as our gold standard to which we could 
compare our real time-PCR copy number results. In order to determine 
were normalized to germline controls with diploid
 
A, B) Real time
a subset of our cell lines by copy 
∆∆
 PIK3CA gene status
graphs). 
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-PCR was 
Ct, cell lines 
 (not shown on 
 Figure 3 PTEN loss in HNSCC cell lines. 
described above on HNSCC cell lines in order to determine whether loss of the 
gene occurred in any of 
demonstrated that PTEN 
line. We therefore used that cell line as a control to validate our experiment. In order to 
determine ∆∆Ct, cell lines were normalized to germline controls with normal 
 
A, B) Real time-PCR was performed as 
our cell lines. Previous publications (described above) have 
is homozygously deleted in PC3 cells, a prostate cancer cell 
dosage (only shown on Figure B). 
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mutation that is not observed in patients (Tables 4) had an IC50 of ~4 µM. Surprisingly, 
all cell lines with PIK3CA gene amplification, regardless of mutation status (see PCI6A, 
Figure 4), were resistant to treatment with BYL719 within the range of the study 
(12.12+/-4.58 µM). Not surprisingly then, the overall half maximal inhibitory 
concentration for this group was not significantly different from the PIK3CA WT cluster 
(P=0.248) (Figure 4B). 
 The p110α catalytic subunit has a RAS binding domain, which can both activate 
and augment PI3K/AKT signaling (29,33,41). RAS activation may also leads to 
alternative downstream activation of mTORC1 activity through the mitogen-activated 
protein kinase (MAPK) pathway (33), and mutations have shown to predict resistance to 
PI3K inhibition in other cancers (33,41). Unsurprisingly then, it was predicted that cell 
lines containing an HRAS mutation would be resistant to BYL719 treatment. Our lab has 
shown that three HNSCC cell lines had HRAS hotspot mutations (Nichols et al., 
unpublished), however none of these had a concomitant PIK3CA alteration. As predicted, 
all three were resistant to BYL719 treatment (Figure 4A).  
 Finally, cell lines devoid of PIK3CA hotspot mutations or gene amplification 
varied in their response to BYL719, with the majority being resistant (9.24+/-5.69 µM). 
One cell line was deemed sensitive, JHU-011, and two others HPV-positive cell lines 
(UM-SCC47 and UPCI:090) had moderate sensitivity (denoted by blue shading in Figure 
4A). HPV-positivity did not seem to affect BYL719 sensitivity. This can be deduced 
primarily because HPV-positive cell lines, denoted by bolding and asterisks, did not 
respond with any visible trend. Instead, cell lines tended to cluster according to PIK3CA 
status (Figure 4). 
3.4 PIK3CA point mutant, but not PIK3CA amplified cell 
lines, are oncogenically dependent on PIK3CA, but not 
AKT1 or mTOR 
 Four HNSCC cell lines, 2 with PIK3CA hotspot mutations (Detroit562, Cal33), 
one PIK3CA-amplified (FaDu), and one with both a point mutation and amplification 
(PCI6A), were subjected to a panel of siRNAs against three key members of the  
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Figure 4 The effects of BYL719 on HNSCC cell lines at 72h. 
with increasing doses of BYL719
PrestoBlue Cell Viability
reported on the X-axis. Cell lines that did not respond be
shaded area. Cell lines that responded below 2
the green shading; Cell lines that responded at a dose above 2
moderately sensitive, as denoted by the blue shading.
computed using non-linear regression; Statistical analysis for each data set was computed 
using a Student’s t-test: B)
amplified vs. non-amplif
C    D 
A) Cell lines were treated 
 and assayed for cell viability at 72h
 assay. Mutational analysis was performed (see abo
low 8µM are denoted in the red
µM were deemed sensitive, as denoted by 
µM were 
 B-D) Mean difference +/
 PIK3CA mutant vs. non-mutant (P=0.011), C)
ied non-mutant (P=0.248), and D) PIK3CA mutant vs. 
amplified (P=0.003).  
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PI3K/AKT signaling axis, PIK3CA, AKT1, and mTOR. The rationale of this study was to  
determine whether PIK3CA points mutations and/or amplifications were the oncogenic 
driving factors in these cell lines. Immunoblots were performed in parallel to demonstrate 
the effectiveness of siRNA knockdown on respective components.   
 Both cell lines with a PIK3CA point mutation (Detroit562, Cal33) showed 
significant reduction in cell viability compared to scrambled siRNA treated controls 
when treated with siRNAs against PIK3CA (p<0.05) (Figure 5A,B). In contrast, both cell 
lines with PIK3CA amplifications showed no decrease with similar siRNA treatment 
(Figure 5C,D). Moreover, siRNA targeting of either AKT1 or mTOR showed no 
difference in any of the cell lines in terms of cell viability as compared to siRNA-
scrambled treated controls (Figure 5). This is interesting because AKT1 and mTOR are 
the two major effectors of canonical PI3K/AKT signaling (31); as such, the persistent cell 
viability in cell lines with singular knockdown of both of these two key components is 
suggestive that they play a less prominent role in PIK3CA-mediated oncogenesis. On the 
other hand, AKT and mTORC1 inhibition (in this case through mTOR knockdown) 
initiates feedback loops that aim to reactivate PI3K signaling through the upregulation of 
RTK expression and recycling maintaining PI3K/AKT signaling and could explain my 
results (103,104).  
 Interestingly, knockdown of PIK3CA in the FaDu and PCI6A cell lines was 
ineffective at reducing viability, despite both cell lines harboring PIK3CA amplifications. 
This would imply that PIK3CA amplification in these cell lines is not in fact the 
oncogenic driver, or at least not the only one. These results moreover show a similar 
result to what was observed with BYL719 in that PIK3CA-amplified cell lines are not 
responsive to PIK3CA inhibition alone. These findings suggest that different PIK3CA 
mutations, in this case hotspot point mutation and amplifications, have different 
responses to small molecule inhibition.  
 
 
 
 A    
C    
E 
Figure 5 Effects of siRNA targeting of key members of the PI3K/AKT axis in 4 
HNSCC cell lines. A) Cal33, B) Detroit562, C) FaDu, and D)
subjected to siRNA-mediated knockdown of
cell viability at 96hrs post transfection. E)
siRNA targeting. All siRNA cell viability effects
(not shown). *Denotes statistical significance from si
P<0.05 using a on
       B 
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3.5 BYL719 is effective at preventing tumor growth in 
PIK3CA-hotspot mutant cell line-derived and patient-
derived xenografts 
 Two cell line-derived NSG mouse xenografts were established to test the effects 
of BYL719 in an in vivo model and determine whether the findings correlated with in 
vitro findings presented above. The H1047R PIK3CA-mutant BYL719-sensitive Cal33 
cell line, and the PIK3CA-amplified, HPV-positive, BYL719-resistant 93-VU-147T cell 
line were chosen for the study. Cal33 was chosen because it was the most sensitive cell 
line to BYL719 (Figure 4A); conversely, 93-VU-147T was chosen not only because it 
was highly resistant, but also because it had the highest CNV of the PIK3CA gene (Figure 
2A).  
 After 13 days, mean tumor volumes reached 200 mm3 and two doses of BYL719, 
25mg/kg and 50mg/kg (105, as well as calculations performed by Dr. Ailles and our lab), 
and a corn oil-treated control, were administered to mice randomly divided into three 
groups of 5. Tumor volume was measured every other day, as described in the materials 
and methods. After 13 days on BYL719 treatment (Day 26), Cal33 xenograft mice 
showed significant decreases in tumor growth and volume at both BYL719 treatment 
doses as compared to the corn oil-fed controls (p=0.01 for both doses). Moreover, on 
average at the 50mg/kg treatment dose, tumor volume did not increase (=200mm3) over 
the 13-day course of the study (Figure 6A), which demonstrates that BYL719 was 
effective in tumors with PIK3CA point mutations. Conversely, the 93-VU-147T 
xenograft mice showed no difference at either of the two BYL719 doses (Figure 6B), 
which agreed with our in vitro findings. 
 We also sought to determine the effects of BYL719 on patient-derived xenografts 
(PDX). One PIK3CA E545K mutant tumor (London 26) successfully engrafted into NGS 
mice, and was subjected to two treatment groups, 50mg/kg of BYL719 or corn oil 
placebo control (Figure 7). BYL719 treatment commenced in PDXs once tumors were 
palpable, roughly around 28 days. By day 44, a difference could be observed between the 
BYL719-treated and untreated mice groups (Figure 7A). The study was terminated once 
tumors in the control group reached the maximum allowed size of 1.5 cm (Day 48).  
 Figure 6 The effects of BYL719 on tumor growth in cell line
xenografts. A) Cal33 (H1047R) and B)
cell lines were injected into the flank of NGS mice to generate tumors. Once t
reached a volume of 200mm
Tumor volume was measured daily. Statistical analysis revealed a significant difference 
for both doses as compared to untreated control in 
Conversely, the 93-VUT
as compared to the untreated control. Results generated by Dr. Laurie Ailles
 
 
-derived mouse 
 93-VU-147T, HPV-positive PIK3CA
3
, one of three treatments was administered (listed above). 
the Cal33-derived xenografts (p<0.
-147-derived xenograft did not observe a difference
52 
 
 amplified, 
umors 
05). 
 at any dose 
 
 A 
B 
Figure 7 The effects of BYL719 on tumor growth in pat
xenografts. London 26 
Average tumor volume (in mm
day period of treatment. BYL719 was administered at day 28 when tumors 
palpable. Drug was administered by oral gavage 5 days/week for 48 days when control 
mice reached their end point. * Denotes statistical significance from corn 
using a two-tailed T-test (p<
without BYL719 treatment at 50 mg/kg. *Denotes statistical significance from corn 
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BYL719-treated tumors were on average about half the size of untreated tumors. This 
was also the case with tumor weight, as on average, BYL719-treated tumors weighed half 
as much as untreated tumors, which was significantly different (Figure 7B). These 
findings seemingly validated the observation that BYL719 was effective at targeting 
PIK3CA point mutations, but not PIK3CA amplifications in cell line-derived HNSCC 
tumors. Additional studies are needed to determine the effects on PIK3CA-amplified and 
WT PDXs. The encouraging results have demonstrated the effectiveness of BYL719 in 
preclinical models. Moreover, our xenograft studies validate our in vitro work with 28 
HNSCC cell lines and have demonstrated a preferential response in PIK3CA point mutant 
systems.  
3.6 Persistent mTORC1 activity as evident by S6 
phosphorylation was consistent in all BYL719 resistant 
PIK3CA-amplified cell lines 
 The results from Figures 4, 6 and 7 demonstrate that PIK3CA amplification, 
regardless of mutation status, is a predictive marker of BYL719 resistance. We therefore 
sought to compare the effects of BYL719 inhibition on downstream effects of activated 
AKT (p-AKT T308, S473), and mTORC1 in sensitive and resistant PIK3CA-altered cell 
lines (Figure 8). The mTORC2 complex, while able to phosphorylate AKT at Serine 473 
(31), to our knowledge plays a much less prominent role in PI3K/AKT signaling 
compared to mTORC1. It is postulated instead to be more actively involved in the 
organization of the actin cytoskeleton (39,132). For this reason, preliminary studies 
focused on AKT-mTORC1 signaling.  
 Four cell lines, Detroit562, Cal33, PCI6A, and FaDu, were treated with BYL719 
for 36h to observe and compare the effects of drug inhibition on PI3K/AKT pathway 
signaling (Figure 8A). In sensitive cell lines, BYL719 was effective at drastically 
reducing the phosphorylation of AKT at threonine 308 and serine 473, and also 
subsequent mTORC1 activation, as measured by S6 phosphorylation at both serine 235 
and 236 (11.25+/-0.9 % of control). Conversely however, resistant cell lines showed 
persistent activation of p-S6 (S235/6), albeit reduced from the untreated control, despite 
 A 
B 
Figure 8 The effects of BYL719 on downstream componenets of the PI3K/AKT 
signaling pathway A) Resistant lines 
and sensitive lines Detroit562 and Cal33 (both H1047R), we
36h to assess the effects of drug inhibition on downstream pathway components. 
Immunoblots reveal decreased phosphorylation AKT (Thr308, Ser473) in all cell lines; 
pS6 (235/6) was maintained
(Ser235/6) in PIK3CA amplified (PCI6A
 
PCI6A (amplified, E545K) and FaDu (amplified), 
re treated with BYL719 for 
 in resistant cell lines. B) Percentage of S6 phosphorylation 
), BYL719 resistant (n=5), and 
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BYL719 sensitive (n=2) cell lines. ImageJ was used to compute densitometry. A paired 
T-test demonstrated a trend towards significance between the two groups (P=0.0831) 
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reduced p-AKT (T308, S473) (Figure 8A). Quantification of knockdown by densitometry 
clearly shows reduced S6 phosphorylation levels (S235/6) at 5µM in BYL719 sensitive 
cell lines (Figure 9B). This trend of maintained mTORC1 activity as a means for 
resistance through S6 phosphorylation was evident for 3 additional cell lines harboring 
PIK3CA amplifications (49.96+/-12.06 % of control) (Figure 8B). A paired T-test 
demonstrated a trend towards a significant difference between the sensitive and resistant 
cell line populations (P=0.0831), and the means of each group demonstrated greater 
levels of S6 phosphorylation in the BYL719 resistant population (49.96+/-12.06 % of 
control, for resistant vs. 11.25+/-0.9 % of control, for sensitive). 
3.7 AKT phosphorylation at Serine 473 is maintained after 
BYL719 treatment in HPV-positive HNSCC cell lines 
 HPV-positive and HPV-negative HNSCC are two very distinct disease states as has 
been previously discussed (6-14). Considering this, we sought to determine if HPV 
infectivity in HNSCC cell lines showed a different phenotypic response to BYL719. 
Eleven HNSCC cell lines were treated with increasing doses of BYL719 (0,1,5,10µM) 
for 36h.  All cell lines showed effective knockdown of AKT phosphorylation at threonine 
308. Moreover, mTORC1 activity as determined by S6 phosphorylation depended more 
so on PIK3CA amplification status rather than the presence of HPV (Figure 8). However, 
it was observed that HPV-positive cell lines showed persistent AKT phosphorylation at 
the secondary AKT phosphorylation site, Serine 473, after BYL719 treatment (Figure 9). 
 Four HPV-positive, and 7 HPV-negative cell lines were studied in order to analyze 
the observation that AKT phosphorylation at Serine 473 was maintained after BYL719 
treatment. Cell lines were chosen to represent the full panel of PIK3CA insults examined 
in this thesis (Table 1). The HPV-positive cell lines were 93-VU-147T, HMS001, 
UPCI:154, and UM-SCC47. The HPV-negative cell lines were FaDu, PCI6A, Cal33, 
Detroit562, Cal27, JHU006, and SCC15. The levels of AKT phosphorylation in all HPV-
positive cell lines were assayed after 5µM BYL719 treatment (Figure 9A). Five 
micromolar of BYL719 was the dose chosen for analysis because all sensitive cell lines 
responded to doses considerably below this concentration, and all resistant cell lines 
showed no response at this dose. 
 A 
B 
C 
Figure 9 The effects of BYL719 on phospho
cell lines. Eleven HNSCC cell lines, 4 HPV
with escalating dose of BYL719 in order to observe the effects of drug inhibition on AKT 
phosphorylation at Serine 473. A) Immunoblotting of 4 HPV
4 HPV-negative cell lines; for the HPV
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phosphorylation at Serine 473. C) Quantification and comparison of phospho-AKT 
(Ser473) levels at 5µM BYL719 in HPV-positive and negative cell lines. Densitometry 
was computed using ImageJ. Statistical analysis using a One-tailed Student’s t-test 
revealed that HPV-positive cell lines had significantly higher levels of pAKT(Ser473)  as 
compared to HPV-negative cell lines (p= 0.0157, Mean ± SD: HPV-, 19.764 ± 13.216 
densitometry units, N=7; HPV+, 84.990 ± 58.150 densitometry units, N=4). 
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 Three of the four HPV-positive cell lines had maintained levels of AKT 
phosphorylation at Serine 473 that was similar to untreated controls after 5µM treatment 
with BYL719 (Figure 9A). Conversely, AKT S473 phosphorylation in HPV-negative cell 
lines was dramatically reduced after similar treatments with BYL719 (see Figure 9B). 
Quantification of phospho-AKT levels as a percent of untreated controls demonstrates the 
great discrepancy in BYL719’s effect at reducing AKT phosphorylation in HPV-positive 
cell lines as compared to HPV-negative cell lines (Figure 9C). Statistical analysis using 
an unpaired Student’s t-test revealed that levels of phospho-AKT (S473) were 
significantly higher in HPV-positive cell lines as compared to HPV-negative cell lines 
(p=0.0157, Mean ± SD: HPV+, 19.764 ± 13.216 densitometry units; HPV-, 84.990 ± 
58.150 densitometry units) (Figure 9C). The only cell line that didn’t show decreased 
phosphorylation of AKT phosphorylation at Serine 473 in the HPV-positive group was 
UPCI:154. Interestingly, the UM-SCC47 cell line also maintained AKT S473 
phosphorylation despite being moderately sensitive to BYL719. This would imply that 
maintained AKT S473 phosphorylation does not mediate resistance to BYL719 in HPV-
positive cell lines.      
3.8 HNSCC cell lines are resistant to rapamycin, an 
mTORC1 inhibitor  
 All PIK3CA-amplified cell lines showed persistent mTORC1 activity evident by 
S6 phosphorylation (Figure 8) suggesting that mTORC1 was in fact the major effector to 
target in these cell lines with PIK3CA gene amplification. Therefore, we sought to 
determine whether targeting mTORC1 with rapamycin in PIK3CA-amplified, BYL719 
resistant cell lines would be effective.  
 Rapamycin (sirolimus) is a macrocyclic antibiotic first isolated from the 
bacterium Streptomyces hygroscopicus (30). It is the first known inhibitor of mTORC1, 
and preceded other mTOR inhibitor compounds such as temsirolimus (CCI779), 
everolimus (RAD001), and deforolimus (AP23573) (32). Rapamycin functions by 
binding to a hydrophobic pocket in the FKBP12, a protein folding chaperone for proteins 
with proline residues (133). This protein-drug complex further binds to the FRB domain 
of mTOR, thereby inhibiting its activity (103). Rapamycin is only truly effective at 
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inhibiting mTORC1, as previously alluded to (see Introduction 1.3 PI3K/AKT Pathway) 
and is an FDA approved cancer therapeutic.  
 Nine HNSCC cell lines, 93-VU-147T, HMS001, UPCI:090, UPCI:154, FaDu, 
PCI6A, UM-SCC47, Detroit562, and Cal27, were subjected to increasing doses of 
rapamycin (Figure 10A). Cell lines were chosen to represent H1047R point mutants, 
PIK3CA amplifications, and PIK3CA WT clusters (Table 1). I also sought to determine if 
two of the PIK3CA WT cell lines that were sensitive to BYL719, UM-SCC47 and 
UPCI:090, were also sensitive to rapamycin treatment. Only one of the cell lines 
(UPCI:090) reached an IC50 at the upper most dosage of 10µM after 72h of treatment 
(Figure 10A). It can be deduced that for most HNSCC cell lines, singular mTORC1 
targeting is ineffective at decreasing the viability of cell lines with PIK3CA insults. 
 Effective decrease in mTORC1 activity was determined by performing 
immunoblot analysis of S6 phosphorylation. Three cell lines, Cal27, 93-VU-147T, and 
FaDu (Figure 10B-D), were chosen and treated with increasing doses of rapamycin. 
Immunoblot analysis revealed that two cell lines, FaDu and 93-VU-147, both 
experienced drastic decrease in S6 phosphorylation at 100nM of rapamycin, whereas 
Cal27 experience considerable reduction at 1nM (Figures 10B-D). It can be inferred then 
that mTORC1 activity was sufficiently decreased in the cell viability studies in Figure 
10A, thereby demonstrating that alone, rapamycin is unable to thwart growth in HNSCC 
cell lines.   
 Since all PIK3CA-amplified cell lines were resistant to both seperate treatments of 
BYL719 and rapamycin, despite having a known oncogenic driver mutation and 
persistent mTORC1 activity, I postulated that combiation therapy of both drugs in these 
cell lines would effectively reduce PI3K/AKT pathway signaling, and therefore reduce 
cell viability. In order to do this, the half maximal drug concentration of rapamycin had 
to first be determined. Four HNSCC cell lines, Cal33, FaDu, PCI6A, and 93-VU-147T, 
were treated with increasing concentrations of rapamycin that were above the maximal 
dose in Figure 10A. Three of the 4 cell lines responded to rapamycin treatment at a 
concentration between 30 and 40µM (Figure 11). FaDu responded to treatment above 
 A 
B    
D 
Figure 10 The effects of rapamycin in a panel of HNSCC cell lines at 72h. 
HNSCC cell lines were treated with increasing doses of rapamycin and assayed for cell 
viability using the Presto
FaDu, Immunoblots
phosphoryla
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 Blue Cell Viability Reagent. B) Cal27, C) 93
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tion with increasing doses of rapamycin. 
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 Figure 11 Determination of the effective rapamycin dose for combination studies 
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treatment was determined by generating growth curves to extrapolate a proper dose to use 
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50µM. In order to perform combination therapy, a lower dose of rapamycin that had no 
effect on HNSCC cell line growth had to be chosen in order to potentially observe a 
synergistic effect with BYL719. Studies have shown that in order to observe a synergistic 
effect in combination therapy studies, independent of drug toxicity, a dose considerably 
below the IC50 needs to be used (125-128). Studies using rapamycin specifically have 
suggested a dose that is 20% the IC50 from in vitro cell line testing is sufficient for 
combination therapy (125,126). Therefore, 6µM of rapamycin was used for combination 
therapy with BYL719, which was 20% the IC50 of 3 of 4 cell lines tested in Figure 10.  
3.9 HNSCC cell lines with PIK3CA amplifications that were 
resistant to BYL719 treatment are sensitive to 
combination treatment of BYL719 and rapamycin 
  HNSCC cell lines with PIK3CA amplification did not respond to singular 
treatment of BYL719 nor rapamycin. BYL719 treatment revealed effective knockdown 
of AKT phosphorylation in these cell lines, however mTORC1 activity, as determined by 
S6 phosphorylation, was maintained (Figure 8). mTORC1 initiates many important 
functions in the cell (31,33,35,36-38), and is therefore a logical candidate for targeted 
therapy. Targeting of mTORC1 with rapamycin in a panel of HNSCC cell lines was 
largely ineffective, with the exception of one cell line (UPCI:090), which was also 
moderately sensitive to BYL719, yet does not contain any known PIK3CA, or PI3K/AKT 
pathway alterations. I sought to determine whether combinatory therapy of HNSCC cell 
lines with BYL719 and 6µM of rapamycin was more effective (Figure 12). 
 PIK3CA-amplified cell lines 93-VU-147T, SCC15, PCI6A, FaDu, and HMS001, 
and PIK3CA WT cell lines Cal27, UPCI:154, and JHU006 were treated with increasing 
doses of BYL719, while maintaining a constant rapamycin concentration of 6µM. Cell 
viability was measured at 72h (Figures 12) and 96h (data not shown) in order to 
determine the effects of combinatory drug therapy on BYL719 resistant cell lines. All 
PIK3CA-amplified cell lines responded to combination treatment, which resulted in a 
BYL719 half maximal inhibitory concentration that was significantly lower than BYL719 
 A    
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Figure 12 The effects of combination therapy on a panel of HNSCC cell lines at 72h. 
A) PCI6A, B) FaDu, C) 
with 6µM and 30µM rapamy
JHU006, and I) UPCI:154
BYL719 and 6µM rapamycin and compared to BYL719 alone. Cell viability was 
determined using PrestoBlue Reagent at 72h
compare decreased signaling (as determined by phosphorylation) of PI3K/AKT pathway
between the two treatments. Phospho
used as markers to determine effectiveness of drug treat
using a one-way ANOVA with Tukey’s range test (*denotes P<0.05, and **P<0.001 in 
order to appreciate the significance of the effect of combination therapy)
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treatment alone (Figure 12). PCI6A and FaDu, both of which were shown to be resistant 
to BYL719, and not solely oncogenically dependent on PIK3CA (Figure 5), were 
sensitized to BYL719 when used in combination with rapamycin (Figure 12A-C). 
However, PCI6A, which harbors both an E545K point mutation and gene amplification 
showed the least dramatic response to combination therapy (~5µM in combination vs. 
10µM with BYL719 alone) (Figure 12A,C). The HPV-positive cell line, 93-VU-147T, 
showed the greatest difference in response, as BYL719 treatment alone yielded an IC50 
considerably above the 8µM limit (Figure 12D) (non-linear regression extrapolated IC50 
of 40.27µM), whereas combination therapy with rapamycin lowered the IC50 to 0.89µM 
at 72h (Figure 12D), and >1µM at 96h (data not shown). All other PIK3CA-amplified cell 
lines tested also showed increased sensitivity to BYL719 when used in combination with 
rapamycin (Figure 12E-G). 
 Quantification of combination therapy IC50 compared to BYL719 alone IC50 was 
performed using non-linear regression to ascribe values to responses outside the 10µM 
study limit (Figure 13). Cell lines that had a half maximal inhibitory concentration above 
15µM were ascribed a value of 15 for statistical analysis (denoted by * in Figure 13). The 
mean IC50 of PIK3CA-amplified cell lines after combination therapy (4.37±1.60 µM) was 
significantly lower (p=0.0002) to the IC50 of the same cell lines under BYL719 treatment 
alone (11.74±2.05 µM) (Figure 13) or rapamycin alone (Figure 10).  
 None of the three PIK3CA WT cell lines showed a response to combination 
treatment of BYL719 and 6µM rapamycin, which was not significantly different from 
BYL719 alone treatment (Figure 12G-I). Statistical analysis revealed no significant 
difference at any of the doses in either treatment (Figure 12G-I). This would imply these 
cell lines are not oncogenically dependent on PI3K/AKT signaling for survival. This is in 
contrast to the PIK3CA-amplified lines, which require both mTOR and PIK3CA 
inhibiton, and the PIK3CA mutant lines that require solely PIK3CA inhibition. These 
findings provide valuable information in understanding the differential response of 
PIK3CA mutations to BYL719 treatment.  
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3.10 PIK3CA and SOX2 co-amplification was common in 
many HNSCC cell lines  
 siRNA knockdown of PI3K/AKT pathway components demonstrated that 
PIK3CA-amplified cell lines were not oncogenically dependent solely on PIK3CA 
signalling (Figure 5). This is supported by the fact that all PIK3CA-amplified cell lines 
were resistant to singular BYL719 treatment (Figure 4). We sought to query the 3q26 
chromosomal region for alternative proto-oncogenes that may explain resistance to 
BYL719. This region, which includes the PIK3CA gene, is frequently amplified in head 
and neck cancer (6,TCGA, www.cbioportal.org).  
 A retrospective analysis of the most recent TCGA CNV data from 10 different 
cancers revealed that HNSCC had the second highest overall rate of PIK3CA 
amplifications, with ovarian cancer having the greatest increase in copy number (Figure 
14A). Furthermore, HPV-driven cervical cancer and smoking-induced lung SCC had the 
third and fourth most PIK3CA amplifications (Figure 14A). We next queried the 3q26 
amplicon and identified 4 genes that are proto-oncogenic or tumor suppressive, SOX2, 
TP63, and TERC. A review of these genes and their potential roles in HNSCC can be 
found in a recent review published by our group (Rizzo et al., Oral Disease 2014). These 
three genes are proximal to PIK3CA (178.87-178.96 Mb), with SOX2 being most 
proximal (181.43 Mb), followed by TP63 (189.35-189.62 Mb) downstream, and TERC 
further upstream (169.48 Mb). The RAB7A gene located further upstream (128.44-128.5 
Mb) (TCGA, www.cbioportal.org) was also queried. All co-amplification values were 
normalized to the overall rate of PIK3CA amplification in each cancer in order to show 
an overall rate of co-amplification in all tumors. HNSCC showed the second highest rate 
of PIK3CA co-amplification with SOX2 (20.58%), SOX2 and TP63 (18.83%), and SOX2, 
TP63 and TERC (17.74%), and the highest co-amplification rate with SOX2, TP63, 
TERC, and RAB7A albeit at much lower rates (4.59%) (Figure 14B). Ovarian cancers had 
the highest overall rates of PIK3CA co-amplification with three of the four genes (SOX2, 
TP63, TERC). More importantly, PIK3CA amplifications occurred nearly 100% of the 
time with SOX2 amplifications, in HNSCC with only one tumor not having the co-
amplification event (TCGA, www.cbioportal.org) (Figure 14C). 
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 Considering the nearly 100% correlation between PIK3CA and SOX2 co-
amplification (Figure 14C), we sought to determine whether this phenomenon occurred in 
a panel of HNSCC cell lines. Furthermore, SOX2 has been shown to influence PI3K/AKT 
pathway, particularly mTORC1 activity, in cancer (90) therefore affording us a possible 
explanation for why PIK3CA-amplified cell lines are resistant to BYL719 treatment. 
TRAT1 and germline controls were used to control for ploidy. As was the case with the 
TCGA data, nearly all cell lines with reported PIK3CA amplification also had 
concomitant SOX2 amplification (Figure 14D). Only two of the cell lines, RF15A and 
RF15B, showed PIK3CA amplification without concurrent SOX2 amplification. 
Interestingly, five cell lines previously reported to not have amplifications in PIK3CA, 
JHU006, JHU029, SCC4, SCC9, and UM-SCC47, increases in copy number above the 
threshold set by the germline controls (Figure 14D). UM-SCC47 had considerably higher 
levels of both PIK3CA and SOX2. A logical explanation for this is either a drastic change 
in ploidy number in this cell line, 3p arm deletion, as has been reported in a portion of 
HNSCC (7). We are currently characterizing our entire panel of cell lines with Oncoscan 
copy number array chips to provide definitive copy number data. 
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4 DISCUSSION 
 This thesis work did not support our initial hypothesis that HNSCC cell lines with 
PIK3CA alterations (i.e. point mutation or gene amplification) would be responsive to 
drug treatment with the alpha specific PI3K inhibitor BYL719. Instead, a preferential 
response to BYL719 was observed in cell lines and xenografts carrying PIK3CA hotspot 
point mutations. Cell lines carrying an amplification of the PIK3CA locus, regardless of 
the mutation status of PIK3CA, were refractory to BYL719 treatment. We found that cell 
lines and xenografts with PIK3CA amplifications were resistant to BYL719 treatments, 
with SCC25 being the only PIK3CA-amplified cell line that partially responded to drug 
treatment within the study range (IC50 ~8µM) (Figure 15). Moreover, the only cell line 
that harbored both a PIK3CA point mutation and amplification, PCI6A, was resistant to 
BYL719, with a profile that mimicked other cell lines with PIK3CA amplifications. This 
is suggestive that resistance to BYL719 is caused by gene amplification rather than the 
activity of the helical domain mutation. 
 Point mutations in PIK3CA occur most commonly at three hotspots: transitions 
(G>A) at both 1781 and 1790 result in non-synonymous substitutions at amino acids 542 
(E>K) and 545 (E>K) in the helical domain. Similarly, a transition (A>G) at 3140 results 
in a non-synonymous substitution at amino acid 1047 (H>R) in the kinase domain 
(Catalogue of Somatic Mutations in Cancer (COSMIC), cancer.sanger.ac.uk). These 
mutations account for greater than 90% of all PIK3CA point mutations (COSMIC, 
cancer.sanger.ac.uk). Helical domain mutations are thought to acquire oncogenic ability 
by weakening key interactions in the N-terminal SH2 (nSH2) domain of p85 thereby 
limiting p85’s negative regulatory effect on the PI3K complex (67). Conversely, the 
H1047R kinase domain mutation occurs at an alpha helix at the end of the activation 
loop. Interestingly, the region of p85 where both the 542 and 545 amino acids of the 
p110α subunit interact also comes into contact with p110α’s kinase domain (67). It is 
therefore possible to hypothesize that helical domain mutations can impact kinase domain 
function. 
   
Figure 15 Summary of the effects of BYL719 on 
and WT HNSCC cell lines. 
mutations (E545K, H1047R) were sensitive to BYL719 treatment and showed decreased 
AKT and mTORC1 activity thereby resulting in a decrease in cell viability. 
cell lines (i.e. no hotpsot point mutations or gene amplifications) also s
AKT and mTORC1 activity, however no decrease in cell viability was observed. Finally, 
PIK3CA-amplified cell lines showed persistent mTORC1 activity when treated with 
BYL719 and therefore no noticeable decrease in cell viability despite decr
phosphorylation of AKT (T308, S473).
rapamycin in PIK3CA
mTORC1, and therefore showed a decrease in cell viability
PIK3CA point mutant, amplified, 
Cell lines or xenografts with PIK3CA hotspot point 
howed decreased 
 However combination treatment of BYL719 and 
-amplified cell lines reduced the activity of both AKT and 
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 PI3K/AKT pathway activation even at basal levels appears so important to 
oncogenicity that certain cancer cells will actively maintain a basal homeostatic level of 
PI3K/AKT signaling, probably due to the large degree of crosstalk it has with adjacent 
pathways (28,41-43,46-48,51). Therefore it might not be surprising that our results 
showed that all PIK3CA-amplified, BYL719-resistant cell lines showed persistent 
mTORC1 activity as evident by the maintenance of phosphorylated S6 (Figure 15). 
Conversely, this was not observed in PIK3CA-point mutated, BYL719-sensitive cell 
lines. Interestingly, the JHU029 cell line, which harbors a H1047L mutation, had a higher 
IC50 than all three H1047R mutants. Huang and colleagues have suggested that amino 
acid substitutions of the 1047 histidine residue shift the hydrogen bonding slightly, 
altering the conformation of the kinase domain (67). The H1047L mutant however is 
incapable of forming proper hydrogen bonds due to the substituted leucine, instead only 
forming weak Van der Waals interactions. This change in kinase domain may explain the 
difference in JHU029’s response to BYL719 (IC50~4µM) as compared to H1047R 
mutants.  
 All PIK3CA WT cell lines were non-responsive to BYL719, and showed a 
detectable reduction in p-AKT (T308, S473) and p-S6 (S235/6). These findings are not 
surprising as PIK3CA WT cell lines are not oncogenically dependent on PI3K/AKT 
signaling for their cancerous phenotype, and therefore inhibition of this pathway has no 
effect on these cell lines (Figure 15). Despite the majority of PIK3CA WT cell lines being 
resistant to BYL719, we did identify 3 cell lines that showed preferential response to 
BYL719; JHU011, UM-SCC47, and UPCI:090. The latter two are HPV-positive, and 
HPV’s use of the PI3K/AKT pathway for constitutive maintenance of viral-protein 
translation could help explain this sensitivity (31). UM-SCC47 and UPCI:090 have also 
been shown to be sensitive to radiation in an AKT-dependent manner compared to HPV-
negative cell lines (136). JHU011, on the other hand, may harbor a non-hotspot mutation 
with oncogenic potential (7,29,67), which would explain its response to BYL719.  
 Immunoblot analysis of HPV-positive HNSCC cell lines after 36h BYL719 
treatment revealed maintained AKT S473 phosphorylation, despite decreased 
phosphorylation at AKT T308 (Figure 9). This could be explained by E7 inhibition of the 
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AKT phosphatase PP2A causing a negative effect on the turnover of the phosphate at 
Serine 473 (31,52,53). This explanation seems more plausible than persistent mTORC2 
activity because treatment of these cell lines with BYL719 and rapamycin was able to 
decrease AKT S473 phosphorylation (Figure 12D and F). Furthermore, this maintained 
AKT S473 phosphorylation did not appear to impact BYL719-response as HPV-positive 
cell lines tended to cluster according to PIK3CA mutational status (Figure 4A). 
 Different PIK3CA hotspot point mutations most likely cannot explain BYL719 
response in HNSCC cell lines. This is supported by studies by Furet and colleagues that 
showed BYL719 has nearly equal dissociation propensities (denoted by Kd values) for 
p110α WT (Kd=5nM), E545K (Kd=4nM), and H1047R (Kd=5nM) (27). All three 
PIK3CA H1047R mutants (Detroit562, Cal33, HSC2) were sensitive to BYL719 
treatment in vitro (Figure 4), with an additional cell line-dervied xenograft (Cal33) 
(Figure 6A), and a PDX harboring a PIK3CA E545K mutation (London26) (Figure 7), 
both being sensitive to BYL719 treatment as well (Figure 15). Only the PCI6A cell line, 
which has both a PIK3CA E545K mutation and gene amplification, was resistant to 
BYL719 treatment suggesting that PIK3CA amplification is the predictative feature of 
BYL719 resistance. Additionally, sequensing data from our lab has shown that only 20% 
of the PCI6A cell line DNA contains the PIK3CA E545K mutation implying that the 
mutation is phylogenically young, and may not constitute a primer oncogenic driver 
event in this cell line (Nichols et al., unpublished). Additional studies will be needed to 
determine whether PIK3CA gene amplification and E545K point mutation in PCI6A 
occur on the same allele. 
 Few studies have suggested that PIK3CA H1047R mutants have a preferential 
response to PI3K/AKT/mTOR pathway inhibitors, as compared to the helical domain 
mutations (131,137). Conversely, and in-line with the data presented, studies with 
BYL719 in breast cancer cell lines in culture and cell line-derived xenografts have shown 
that a significant subset of both helical and kinase domain PIK3CA-mutated cell lines and 
tumors were sensitive to BYL719 treatment with IC50 values and tumor responses similar 
to my study (105). MCF7 and BT483 cell lines, harboring an E545K and E542K PIK3CA 
mutation respectively, were both highly sensitive to BYL719 at doses below 1µM (105) 
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with decreased AKT and mTORC1 signaling (105), which was consistent with our data. 
This trend of BYL719 effectiveness irrespective of mutation type was also observed in 
other cancers (101,138). Studies by Fritsh and colleagues reported a 64% response rate to 
BYL719 of PIK3CA mutant cell lines from all cancers (N=22/34), as well as significant 
reductions in tumor growth in cell line-derived xenografts (101).  
 The rates of PIK3CA hotspot point mutations in patient orophayrngeal tumors 
from the LRCP tumorbank correlated with the rates reported in the current literature 
(6,9,10,11,TCGA www.cbioportal.org). HPV-positive oropharyngeal tumors also had 
significantly higher rates of PIK3CA hotspot point mutation as compared to HPV-
negative tumors. PIK3CA point mutations in non-oropharyngeal tumors were far less 
common than in oropharyngeal tumors, which were also expected (Table 6). The heavy 
dependency of HPV on PI3K/AKT signaling in order to carry out infection and basic 
viral function is suggestive of a commentualistic relationship between the virus and the 
pathway (31,52,53). It has also been reported that the E5 viral protein upregulates and 
maintains the expression of the epidermal growth factor receptor (EGFR), which in turn 
activates PI3K/AKT signaling (139).  
 PIK3CA gene amplification occurred in a major subset of both HPV-positive and 
HPV-negative oropharyngeal tumors. These findings match previous findings reported by 
several groups in which a high incidence of PIK3CA amplifications occured across both 
types of HNSCC (6,9,10,11,TCGA www.cbioportal.org). Moreover, most of these 
studies also remarked on the propensity of dual PIK3CA point mutation and amplification 
in the same tumor, albeit at lower rates than our study (9,TCGA www.cbioportal.org). 
Indeed, our rates of PIK3CA amplification were higher than reported in recently 
published sequencing papers, with HPV-positive HNSCC tumors harboring between 25-
30% amplification, and HPV-negative tumors slightly lower (20%) (7,TCGA 
www.cbioportal.org). This could be explained by our relatively low cut off ∆∆Ct value of 
1 (normalized to patient germline controls), where all tumors with a ∆∆Ct above 1 were 
catagorized as PIK3CA-amplified. Studies have defined one extra gene copy as an 
amplification event (140, TCGA www.cbioportal.org), yet the significance of one extra 
gene copy is debatable as an oncogenic driver event. Multiple studies however have 
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shown that absolute, rather than relative, increase in PIK3CA gene copy correlated with 
increased expression and therefore AKT phosphorylation (129,131,141,142). Conversely, 
expression of the TP63 locus found upstream of PIK3CA on the 3q chromosomal arm 
was more so dictated by relative copy number changes (130). Future studies should seek 
to understand the effects of relative and absolute PIK3CA copy number gains, and assess 
the impact on oncogenicity.  
 The impacts of PIK3CA amplification or point mutation, while both being able to 
drive oncogenesis (22-25,68), in HPV-positive and negative HNSCC are likely different. 
In HPV-negative HNSCC, carcinogenic insult introduces many different chromosomal 
abnormalities (6,12) implying that PIK3CA alterations can occur just as commonly as any 
other gene mutations or amplifications. This could explain why PIK3CA point mutations 
and amplification rates do not stand out from other mutations or amplifications in HPV-
negative HNSCC (TCGA). Conversely, PI3K/AKT pathway activation is strongly tied to 
efficient HPV function (31,52,53). The acquisition of high viral E6 and E7 expression 
would drive the cell into S phase without appropriate checkpoint controls, thereby 
permiting HPV genome replication (143). Moreover, HPV genome fragments expressing 
E6 and E7 can insert into the host’s genome, and indirectly facilitate the amplification of 
proximal genes (56-58,82). However, E6 and E7 insertion seems to occur at random 
(144), therefore viral-directed targeting and subsequent amplification of the PIK3CA 
gene seems unlikely. Nonetheless, amplifications and point mutations in PIK3CA could 
be beneficial to the fitness of HPV in that it dampens stress response, promotes viral 
protein translation, and suppresses apoptosis (31). This relationship is further supported 
by the high propensity of 3q24-29 chromosomal amplifications and PIK3CA mutations in 
cervical cancers (145,TCGA www.cbioportal.org). It is important to note however that 
the purpose of HPV is not to cause cancer; the E6 and E7 viral oncoproteins accelerate 
the differentiation of squamous cells so that infectious HPV-progeny may be released at 
the surface (31,143,146,147). This is supported by the fact E6 and E7 can immortalize 
keratinocytes (146), but cannot cause oncogenic transformation on there own and require 
additional oncogenes (147). It is the oncogenic nature of PIK3CA, rather than the 
presence of HPV, that leads to oncogenic transformation (143). It is possible then to see 
an increased reproductive fitness, and therefore a selection bias, for HPVs that have 
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infected cells with acquired PIK3CA mutations. Given that PIK3CA amplifications and 
point mutations occur at roughly equal rates in HPV-positive HNSCC (6,7,9-11,TCGA 
www.cbioportal.org), it can be assumed that both types of mutations are sufficient in 
driving oncogenesis, and offer an explanantion as to why there is an apparent close tie 
between HPV and PIK3CA mutation rates. 
 The observation that all PIK3CA-amplified cell lines and xenograft were resistant 
to BYL719 went against our initial hypothesis and remains a topic of debate. Most 
studies across different cancers appear to agree that PIK3CA amplification is a marker for 
treatment resistance and poor patient outcomes (81,106,148-150). Yet, some studies have 
shown the opposite (101,129,151). Interestingly, studies by Fritsch and colleagues 
demonstrated in cell lines and cell line-derived xenografts that PIK3CA-amplified models 
were sensitive to BYL719 treatment, however only a few HNSCC cell lines were used in 
that study (101). Instead our results demonstrated in a panel of 29 cell lines, all 11 with 
PIK3CA amplifications and in one cell line-derived xenograft, that amplification 
predicted resistance to BYL719. Resistant cell lines that were HPV-negative but still 
possessed PIK3CA amplifications showed significant reduction of AKT phosphorylation 
at threonine 308 and serine 473 after treatment with BYL719. This decrease in phospho-
AKT (T308, S473) mirrored the response of BYL719-sensitive PIK3CA mutant cell 
lines.  
 Mechanistically, amplification-driven resistance likely occurs due to insufficient 
drug targeting of the increased numbers of PIK3CA gene product, with the amount of 
drug acting as the limiting factor (148). This principle would agree most convincingly 
with our findings, based on the fact that the 93-VU-147T cell line, as determined by our 
group, has the highest number of PIK3CA gene copies and therefore correspondingly, the 
highest predicted IC50 for BYL719 of 40.27µM. Since the affinity of BYL719 for both 
point mutant and WT p110α is identical, it is unlikely that resistance is explained by 
insufficient drug binding to the WT form (67), as is the case with certain MEK1 
inhibitors (107). Singular targeting of the two key nodes of the PI3K/AKT axis, i.e. AKT 
and mTOR, initiates feedback mechanisms whereby RTKs are re-cycled to the plasma 
membrane and PI3K and/or ERK activity is reinstated (103,104,107,108,152,153). In the 
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context of this study, singular mTORC1 inhibition results in receptor recycling, 
independent of Forkhead box (FOXO) proteins, thereby reactivating PI3K, ERK, and 
AKT signaling (103,104). Mitogen-activated protein kinase (MAPK) signaling (RAS-
RAF-MEK-ERK pathway) moreover is activated by the S6 kinase (S6K)-PI3K-RAS 
feedback loop when faced with mTORC1 inhibition in order to maintain oncogenic 
processes (104). This might provide a means as to why rapamycin inhibition in HNSCC 
cell lines was largely ineffective. Furthermore, it stresses the importance and validity of 
complete and selective PI3Kα inhibition in PIK3CA-altered tumors; not only is it the 
driving force behind the oncogenic phenotype (22-25,68), but it is also the primary node 
of the feedback mechanisms induced by AKT and mTORC1 (104,130). 
 Amplification as a means for acquired resistance and therefore poor prognosis has 
been well documented. Two independent studies have shown that acquired BRAF or 
KRAS amplifications in colorectal cancer cells with previous BRAF mutations become 
resistant to MEK1/2 inhibition (107,109). Moreover, acquired PIK3CA amplification has 
also been shown to mediate a resistant phenotype in breast cancers. Specifically, acquired 
de novo PIK3CA amplification in the H1047R-mutated KPL-4PR cell line are resistance 
to the PI3K inhibitor GDC-0941 (77). While we did not look at novel amplification 
events in this study, we did observe treatment resistance in the only cell line that had both 
a PIK3CA point mutation and gene amplification, PCI6A (Figure 4A).  When considering 
amplification as a singular means for treatment resistance, Turke and colleagues showed 
that MNNG Hos Transforming gene (MET) amplification, a hepatocyte growth factor 
receptor that functions upstream of ERBB3/PI3K/AKT signaling, conferred resistance to 
EGFR inhibition in non-small cell lung carcinomas (106). Moreover, and consistent with 
amplification as a means for poor prognosis, Suda and colleagues identified copy number 
alterations in PIK3CA as a poor prognostic factor in non-lymph node metastatic HNSCC 
(149).   
 In order to explain amplification-mediated resistance, an analysis of possible 
secondary mutations in two of the more proximal proteins to PI3Kα, PTEN and RAS, 
was performed based on their direct involvement in PI3Kα function and their roles in 
driving PI3K/AKT signaling. Previous studies have implicated PTEN loss as a 
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mechanism for resistance to PI3K inhibition (42,101), with more recent work reporting 
that PTEN loss was present at secondary sites refractory to BYL719 treatment in 
PIK3CA-driven breast tumors (42). Moreover RAS mutations, specifically HRAS 
mutations, occur in 5% of HNSCC tumors (6,9-11,TCGA www.cbioportal.org) and have 
strong influence on PI3Kα, particularly with helical domain mutations (69). A strong 
interdependency between the two pathways for effective drug treatment has also been 
reported, as PIK3CA mutation or PTEN loss mediate resistance to MEK inhibitors (154), 
and activating mutations in RAS significantly reduce the efficacy of PI3K inhibitors 
(70,103). HRAS mutations have also been shown to mediate resistance to EGFR tyrosine 
kinase inhibitors (155). Unfortunately none of the cell lines tested showed concomitant 
PIK3CA amplification or mutation with either PTEN loss or HRAS mutations (data not 
shown) and this therefore cannot explain the discrepancy in our results. The three cell 
lines that did have HRAS mutations, RF22B, 37A, and 37B, unsurprisingly were resistant 
to BYL719 treatment. As with PTEN loss, RAS mutations in secondary tumor sites 
refractory to PI3K inhibition could function as a means for resistance, as a positive 
association has been reported between PIK3CA and RAS (NRAS, KRAS, HRAS) mutations 
in treatment refractory tumors across multiple cancers (137). 
 The large degree of crosstalk between the PI3K/AKT and MAPK pathway has 
been alluded to in this report in terms of the interdependency required for effective drug 
treatment (103,154). One study showed that in pituitary gland tumors, PIK3CA 
amplification and RAS mutation rarely occurred together, suggesting an overlapping 
oncogenic role (156). Additionally, another study showed that PI3Kα inhibition in 
PIK3CA-mutated, HER2-amplified breast cancer cell lines resulted in a RAS-independent 
decrease in RAC1/p21-activated kinase (PAK)/protein kinase-C Raf (C-RAF)/MEK/ERK 
signaling (157). Our results clearly show potent maintenance of mTORC1 signaling in 
BYL719-resistant cell lines in the absence of AKT phosphorylation. Moreover, the 
significant decrease in IC50 observed when BYL719-resistant cell lines are treated in 
combination with BYL719 and rapamycin implies that resistance is mediated through 
maintenance of PI3K/AKT pathway integrity and is separate from p-AKT activity 
(Figure 15). It was initially postulated that pathway signaling integrity was maintained 
through activation of the RAS/RAF/MEK/ERK pathway. Activation of this axis can be 
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achieved, much like PI3K/AKT pathway, by growth factor binding to RTKs, which leads 
eventually to phosphorylation and inactivation of the TSC1/2 complex and activation of 
mTORC1 by RHEB-GTP (33,41). Moreover as has been previously discussed, RTK re-
cycling also occurs with both AKT and mTORC1 inhibition in FOXO-dependent and 
independent manners, respectively (33,103,158). Instead, a study conducted by our lab 
revealed combination therapy of BYL719 and trametinib, a potent MEK1/2 inhibitor, did 
not have an observable affect on PIK3CA amplified cell lines (Nichols et al, 
unpublished). Moreover, pathway integrity in HNSCC cell lines was not maintained by 
PI3Kβ activity based on no changes in cell viability observed when treated with the pan-
PI3K inhibitor PX-866 (Nichols et al., unpublished). 
 An alternative means of explaining sustained mTORC1 activity during BYL719 
treatment is by AKT-independent mechanisms of mTORC1 activation. mTORC1 activity 
is closely tied to amino acid availability and does not require AKT input (159). Inhibition 
of glucose transport by BYL719 occurs in a two-fold fashion: insulin receptor (IR)-
insulin receptor substrate-1 (IRS1) signal transduction, as well as FOXO-dependent re-
cycling of IR-IRS1 signal transduction, both dependent on PI3Kα, are inhibited by 
BYL719 (103,104). This is evident by abrogation of AKT phosphorylation. The inability 
to shuttle glucose into the cell results in a low AMP: ATP ratio, sensed by 5’ AMP-
activated protein kinase (AMPK), which inhibits mTORC1 function by phosphorylating 
and activating the GAP activity of the TSC1/2 complex (33). A primary function of 
mTOR proteins is to integrate signals from nutrient and energy sensing with cell 
proliferation (158). Amino acids can be used as fuel by the cell (160), which is especially 
important for cancer cells with an intrinsically high metabolic rate (161). The RAS-
related GTPase (Rag)-family maintains mTORC1 signaling through Raptor interaction in 
an amino acid-dependent manner, and thus affords the cell the ability to undergo cell 
proliferation processes (33,159). Despite explaining an alternative means for mTORC1 
activation, this model is incomplete because it fails to explain the relationship between 
Rag proteins and different PIK3CA mutations, especially when considering that PIK3CA 
amplification and point mutations exert different modes of action. Moreover, the TCGA 
reports only a small percentage of tumors that have both Rag and PIK3CA co-
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mutation/amplification events, suggesting that a Rag mutation across all PIK3CA 
amplifications is unlikely to explain resistance (TCGA www.cbioportal.org).  
 A second mean of AKT-independent mTORC1 activation for explaining 
resistance in PIK3CA-amplified models is through PI3K activation of PDK1 activity. 
Mutations in the PI3K/AKT pathway in HNSCC, outside of PIK3CA and PTEN are rare 
and therefore do not provide an explaination for our results (6,9-11,TCGA 
www.cbioportal.org). Canonical activation of AKT phosphorylation, particularly AKT1, 
by PI3Kα activation alleviates TSC1/2 GAP-activity on RHEB, which activates 
mTORC1 and drives oncogenic functions (31,32,162). One method for oncogenic PI3Kα 
signaling independent of AKT activation is through PI3Kα activation of PDK1 (163). 
Sequestering of PDK1 to the plasma membrane independent of AKT in response to lower 
levels of phosphatidylinositol accumulation, or RTK stabilization leads to the activation 
of serum/glucocorticoid-regulated kinase 3 (SGK3) (33,163). The SGK family of proteins 
shares a high degree of functional and structural similarity to AKT, with growing roles in 
normal and cancer cell signaling (164). PDK1-phosphorylated SGK3 is recruited to 
endosomes in an inter-dependent manner by the nutrient signaling, class III PI3K human 
vacuolar sorting protein 34 (hVps34) (164). hVps34 generates phosphatidylinositol 3-
phosphate (PI(3)P), which localizes phsopho-SGK3 through a N-terminal phox homology 
(PX) domain (165) and is required for full activation of SGK3 (166). hVps34 may in turn 
be modulated by SGK3 (164). Most importantly, hVsp34 activates mTORC1 signaling, 
and complete loss of hVsp34 blocks insulin-dependent phosphorylation of S6K and 
eIF4F activation (167). The proposed phospho-SGK3-hVps34 relationship could promote 
mTORC1-dependent growth through activation of improper nutrient sensing (164). 
Moreover, SGK3 loss, rather than AKT, has been shown to contribute significantly to 
cancer phenotype regression in breast cancer (168), ovarian endometrioid 
adenocarcinoma (169), and prostate cancer studies (170). In terms of this study, 
incomplete knockdown of PIK3CA-amplified gene products, while sufficient to decrease 
AKT signaling, may activate mTORC1 signaling in an SGK3-dependent manner. Further 
studies are needed to elucidate the precise overlap of AKT and SGK family proteins in 
cancer, as well as the precise roles, if any, of SGK3 activation on mTORC1. It would also 
be valuable to look at the effects of singular AKT and SGK3, as well as combination 
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knockdown of these components with BYL719 treatment in order to carefully analyze 
whether resistance is mediated through this mechanism.      
 The final proposed explanation of PIK3CA amplification as a means for BYL719 
resistance is through the co-amplification event of other PI3K/AKT pathway activating or 
associated proto-oncogenes within or near the 3q26 amplicon. Retrospective analysis of 
the TCGA data revealed that head and neck, and for that matter, HPV-associated tumors, 
i.e. head and neck and cervical, show the highest prevalence of PIK3CA amplification, as 
well as amplification of the proximal proto-oncogenes SOX2, and TERC, and the TP63 
tumor suppressor gene (10,155,TCGA www.cbioportal.org). Additionally, the proto-
oncogene RAB7A, located just distal to the aforementioned region, at the 3q28 locus, also 
showed high levels of co-amplification in these cancers, yet at lower rates than SOX2, 
TERC, or TP63 (Figure 14). While site-directed E6 and E7 genome integration at this 
locus is unlikely (144), the advantage of PI3K/AKT pathway activation, in this case by 
PIK3CA amplification, to HPV function has already been discussed; this observation 
suggests that either HPV cancers frequently require activation of the PI3K/AKT signaling 
to progress to malignancy, or that an HPV-related mechanism leads to genetic instability 
in this gene (8,32,33,41). The presence of PIK3CA amplification and also 3q 
amplification in early malignant lesions has been shown to promote progression to 
malignancy in cervical (83) and head and neck cancers (84). 
 Of the candidate genes within the 3q26 amplicon, SOX2 is of particular interest 
because of its potential impact on PI3K/AKT pathway activity (90). The other candidate 
oncogenes or tumor suppresors, while also found within or distal to the 3q26 amplicon, 
do not appear to have a direct effect on PI3K/AKT signaling and therefore are outside the 
scope of this study. A detailed analysis of these genes can be found in a recent review 
published by our group (Rizzo et al., Oral Disease 2014). MYC amplification, found at 
the 8q24 chromosomal region (171), is also appealing, but does not afford an explanation 
for the differences in BYL719 response observed between PIK3CA-amplified and 
mutated cell lines and xenografts. This is primarily because amplifications of the 3q26 
and 8q24 regions are likely independent events (171), demonstrated by the poor overlap 
of tumors with PIK3CA and MYC amplification in HNSCC (TCGA, 
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www.cbioportal.org). Moreover, MYC amplification is equally as common in PIK3CA-
point mutant samples and therefore it would be assumed to drive resistance in these 
models as well (TCGA, www.cbioportal.org).   
 Multiple studies have suggested that it is not PIK3CA amplification, but SOX2 
amplification that is the driver event in 3q amplification (85, 173). This is reinforced by 
our findings that two PIK3CA-amplified cells (FaDu and PCI6A) were resistant to siRNA 
knockdown of PIK3CA (Figure 5), which would imply that PIK3CA is not the sole 
oncogenic driver in these cell lines. We also conducted a preliminary analysis of 
PIK3CA-SOX2 co-amplification in HNSCC cell lines and found that most cell lines 
harbored both CNV events with nearly 100% correlation (Figure 14). Additionally, 
SOX2 expression, irrespective of amplification status, appears to be connected to 
oncogenic processes, as one group confirmed high expression levels of SOX2 
independent of gene amplification in smoking-induced malignancies of the esophagus 
and lung (85). SOX2 encodes a transcription factor that maintains pluripotency in 
undifferentiated stem cells, which is suggestive of an important role in EMT in early 
metastatic events (85,87,174). This is supported by the fact that patients with 3q 
amplification have a worse prognosis than patients with normal diploid number of the 3q 
arm (83,84). Furthermore, SOX2 has been implicated as a lineage-survival oncogene in 
lung and esophageal cancers, meaning that upon dysregulation, its function in lineage 
development affords the cell tumorogenic potential (174).   
 SOX2 amplification alone however cannot cause cells to transform, suggesting 
that multiple cooperating genes are required (85). PIK3CA, on the other hand, can 
sufficiently facilitate and sustain malignant transformation (22-25,68). In lung SCC, co-
amplification of SOX2 and the FGFR2 gene, which functions upstream of PI3Kα 
signaling, can drive the induction of malignancy (85). This demonstrates a potential 
reliance of SOX2 on PI3K/AKT signaling for oncogenesis. Multiple studies have shown 
that SOX2-binding to the mTOR promoter can impact pluripotency (175), but more 
importantly, global mTOR function (176). Specifically, Corominas-Faja and colleagues 
demonstrated that the overexpression of SOX2 in MCF-7 cells favorably impacted 
mTOR and mTOR-associated gene expression. Three notable mTOR-inhibitor genes 
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experienced a negative 3-fold change in expression: PRKAA1, which encodes AMPK, 
DEPTOR, which encodes the mTORC1 inhibitor Deptor, and DDIT4, which is a stress 
response gene (176). Moreover, the insulin receptor, upstream of PI3K/AKT signaling, 
was upregulated by 3-fold, while the expression level of S6K1 was also increased with 
overexpression of SOX2 (176). This provides a rational explanation for potent mTORC1 
activity after PI3Kα inhibition in cells with PIK3CA and SOX2 co-amplification. 
Moreover, one study showed that the only way to suppress the effects of overexpressed 
SOX2 in esophageal cancer cell lines was the complete inhibition of the PI3K/AKT 
signaling axis (90), as was the case with our study. Based on our results, and the known 
evidence for SOX2-PI3K/AKT pathway interplay, further studies should analyze the role 
of SOX2 on the PI3K/AKT pathway in terms of gene expression and pathway activation. 
Moreover, it would also be valuable to study the potential, oncogenic additive effects 
SOX2 overexpression affords to non-cancerous cell lines. Finally, a retrospective study 
of the patient data looking at treatment failure, staging, and progression to metastasis in 
relation to SOX2 status in these tumors would provide valuable inference as to the effects 
of SOX2 on HNSCC cancer progression.    
 Future directions should seek to explain what secondary factors maintain 
mTORC1 activity during BYL719 treatment in PIK3CA-amplified cell lines. A simple 
explanation may be that higher concentrations of BYL719 are needed to sufficiently 
inhibit all active PI3Kα, however this model seems simplistic. The evidence for SGK3 
activation is appealing, although future studies are needed to clearly understand the 
interplay, if any, between phospho-SGK3 and hVps34, and their combined effects on 
mTOR-nutrient sensing. As the intracellular interactome continues to grow, additional 
PI3K/AKT pathway relationships will be elucidated, and should merit individual 
attention due to high degrees of redundancy in signaling. Unfortunately from studies in 
our lab, resistance was not mediated through the RAS/RAF/MEK/ERK pathway despite 
significant interplay between the two axes, yet this will probably not be absolute for all 
pathways and all small molecule inhibitors. Finally, it is our primary hypothesis that co-
amplification of SOX2 is a key mediator of BYL719 resistance. Future studies should 
seek to directly understand the effects of SOX2 on mTOR and mTOR-associated genes in 
HNSCC. Moreover, our lab is currently studying the effects of SOX2 overexpression on 
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BYL719 resistance by using RNAi-knockdown of SOX2 in combination with BYL719 
(Nichols et al., unpublished). If a mutual interdependency between SOX2 and PI3K/AKT 
signaling in HNSCC can be established, then future studies can aim towards firmly 
teasing the precise mechanism.     
 As is the case with any study that uses cell lines, results are inferred from model 
systems that are divergent from the actual tumor biology. Cell lines undergo in vitro 
growth selection introducing changes in ploidy number, chromosomal rearrangements, 
point mutations and amplifications, while requiring an immortilization step in order to 
propagate and persist for many passages. Additionally, tissue culture systems are devoid 
of the tumor microenvironment as well as an active immune system, both of which 
significantly impact tumor activity in patients. Moreover, all HPV-positive HNSCC cell 
lines used in this study were uncharacteristic of regular HPV-positive patients (5,13,14): 
all were from tobacco smokers and/or habitual drinkers, most presented with advanced 
(Grade 3) disease, and/or were immortalized from recurrent tumors (177-180).  
 In order to circumvent the limitations with in vitro work, we generated cell line 
and patient-dervied xenografts in NSG mice. Despite affording the study an 
understanding of drug response with an intact tissue microenvironment and whether 
BYL719 can be effectively delivered to impact tumor growth, the use of 
immunocompromised mice does not allow us to study the effects with an intact immune 
system. Due to the difficulty in establishing patient tumors in immunocompromised mice, 
at the time of writing, we have not had the chance to compare the effects of BYL719 in a 
NSG mouse population harboring PIK3CA-WT, or PIK3CA-amplified patient tumors. 
The advantage of PDX over cell line-derived xenografts is that they are representative of 
actual patient malignancies.  
 Finally, when analyzing real-time PCR amplification data, a clear definition of 
what constitituted an oncogenic amplification in the PIK3CA gene was difficult to 
establish. The TCGA classifies all cell lines with one extra copy of PIK3CA as being 
amplified; therefore we decided that all cell lines or patient samples with a ∆∆Ct<1 
would be called amplified as well. The FaDu and Cal27 cell lines were used as positive 
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and negative controls, however a more appropriate control for normalization in cell line 
studies would have been any diploid cell line rather than the germline, patient controls we 
used. Future studies should seek to understand the significance of one to multiple extra 
gene copies on oncogenic transformation 
 The advent of NGS has revolutionized the way we look at cancer biology, and 
cancer treatment. Specifically in head and neck cancer, it has elucidated the key 
underlying differences between HPV-positive and HPV-negative disease states, while 
providing a detailed summary of which mutations are present at high percentages, and 
which ones are amenable to targeting. As has been previously discussed, PIK3CA is the 
only directly, drug targetable oncogene with much greater frequencies in HPV-positive 
disease. As such, this study aimed to first identify a target for small molecule inhibition, 
followed by the elucidation of biomarkers and mechanisms of resistance and sensitivity. 
As has been outlined in this discussion, cell lines with PIK3CA H1047R mutations are 
exquisitely sensitive to BYL719. Conversely however, cell lines with PIK3CA 
amplification or co-mutation and amplification are resistant. This was further 
demonstrated in cell line-derived, and patient-derived HNSCC xenografts, confirming the 
effectiveness of BYL719. Through this study, I was able to demonstrate that all resistant 
cell lines had some degree of mTORC1 activity when treated with BYL719. 
Additionally, most HPV-positive cell lines maintained AKT phosphorylation at Serine 
473 during BYL719 treatment as well. More importantly however, and irrespective of 
HPV-status, combination therapy specific for the oncogenic PIK3CA, and the effector of 
resistance mTORC1, managed to reverse this resistance and reduce cell viability. The use 
of combination therapy probably has a greather effect over dual-PI3K-mTOR inhibitor 
because each drug is able to inhibit one specific component thereby ensuring maximal 
downregulation of target activity. The significance of this research should translate 
directly into clinical practice, where I predict that only patients with PIK3CA mutant, and 
not PIK3CA amplified tumors, should receive BYL719 treatment. Moreover, a 
combination therapy of BYL719 and an inhibitor of mTORC1 (mTORC2 impact merits 
further attention as well) would instead be predicted to be most effective for those 
patients with PIK3CA amplifications. The need for pre-clinical research studies of drug 
effectiveness is vital, with the ultimate goal to predict how tumors will respond. 
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However, when cancer cells prove to be inexplicably irresponsive, such as I found in my 
studies, or become refractory to drug treatment this provides researchers an opportunity 
to understand the underlying mechanisms of resistance. It is these studies that may lead to 
appropriate clinically useful counter measures based on combination therapy.  
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